--12-312024Q30000896622falsehttp://fasb.org/us-gaap/2024#PrepaidExpenseAndOtherAssetsCurrenthttp://www.aptargroup.com/20240930#AccountsPayableAccruedLiabilitiesAndDerivativeLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#PrepaidExpenseAndOtherAssetsCurrenthttp://www.aptargroup.com/20240930#AccountsPayableAccruedLiabilitiesAndDerivativeLiabilitiesCurrentxbrli:sharesiso4217:USDiso4217:USDxbrli:sharesatr:buildingxbrli:pureatr:extensioniso4217:EURatr:segmentatr:company00008966222024-01-012024-09-3000008966222024-10-2100008966222024-07-012024-09-3000008966222023-07-012023-09-3000008966222023-01-012023-09-3000008966222024-09-3000008966222023-12-310000896622us-gaap:RetainedEarningsMember2023-06-300000896622us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300000896622us-gaap:CommonStockMember2023-06-300000896622us-gaap:TreasuryStockCommonMember2023-06-300000896622us-gaap:AdditionalPaidInCapitalMember2023-06-300000896622us-gaap:NoncontrollingInterestMember2023-06-3000008966222023-06-300000896622us-gaap:RetainedEarningsMember2023-07-012023-09-300000896622us-gaap:NoncontrollingInterestMember2023-07-012023-09-300000896622us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300000896622us-gaap:CommonStockMember2023-07-012023-09-300000896622us-gaap:TreasuryStockCommonMember2023-07-012023-09-300000896622us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300000896622us-gaap:RetainedEarningsMember2023-09-300000896622us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300000896622us-gaap:CommonStockMember2023-09-300000896622us-gaap:TreasuryStockCommonMember2023-09-300000896622us-gaap:AdditionalPaidInCapitalMember2023-09-300000896622us-gaap:NoncontrollingInterestMember2023-09-3000008966222023-09-300000896622us-gaap:RetainedEarningsMember2024-06-300000896622us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300000896622us-gaap:CommonStockMember2024-06-300000896622us-gaap:TreasuryStockCommonMember2024-06-300000896622us-gaap:AdditionalPaidInCapitalMember2024-06-300000896622us-gaap:NoncontrollingInterestMember2024-06-3000008966222024-06-300000896622us-gaap:RetainedEarningsMember2024-07-012024-09-300000896622us-gaap:NoncontrollingInterestMember2024-07-012024-09-300000896622us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300000896622us-gaap:CommonStockMember2024-07-012024-09-300000896622us-gaap:TreasuryStockCommonMember2024-07-012024-09-300000896622us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300000896622us-gaap:RetainedEarningsMember2024-09-300000896622us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300000896622us-gaap:CommonStockMember2024-09-300000896622us-gaap:TreasuryStockCommonMember2024-09-300000896622us-gaap:AdditionalPaidInCapitalMember2024-09-300000896622us-gaap:NoncontrollingInterestMember2024-09-300000896622us-gaap:RetainedEarningsMember2022-12-310000896622us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000896622us-gaap:CommonStockMember2022-12-310000896622us-gaap:TreasuryStockCommonMember2022-12-310000896622us-gaap:AdditionalPaidInCapitalMember2022-12-310000896622us-gaap:NoncontrollingInterestMember2022-12-3100008966222022-12-310000896622us-gaap:RetainedEarningsMember2023-01-012023-09-300000896622us-gaap:NoncontrollingInterestMember2023-01-012023-09-300000896622us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300000896622us-gaap:CommonStockMember2023-01-012023-09-300000896622us-gaap:TreasuryStockCommonMember2023-01-012023-09-300000896622us-gaap:AdditionalPaidInCapitalMember2023-01-012023-09-300000896622us-gaap:RetainedEarningsMember2023-12-310000896622us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310000896622us-gaap:CommonStockMember2023-12-310000896622us-gaap:TreasuryStockCommonMember2023-12-310000896622us-gaap:AdditionalPaidInCapitalMember2023-12-310000896622us-gaap:NoncontrollingInterestMember2023-12-310000896622us-gaap:RetainedEarningsMember2024-01-012024-09-300000896622us-gaap:NoncontrollingInterestMember2024-01-012024-09-300000896622us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-09-300000896622us-gaap:CommonStockMember2024-01-012024-09-300000896622us-gaap:TreasuryStockCommonMember2024-01-012024-09-300000896622us-gaap:AdditionalPaidInCapitalMember2024-01-012024-09-300000896622srt:MinimumMember2024-01-012024-09-300000896622srt:MaximumMember2024-01-012024-09-300000896622srt:EuropeMemberatr:AptarPharmaMember2024-07-012024-09-300000896622srt:NorthAmericaMemberatr:AptarPharmaMember2024-07-012024-09-300000896622srt:LatinAmericaMemberatr:AptarPharmaMember2024-07-012024-09-300000896622srt:AsiaMemberatr:AptarPharmaMember2024-07-012024-09-300000896622atr:AptarPharmaMember2024-07-012024-09-300000896622srt:EuropeMemberatr:AptarBeautyMember2024-07-012024-09-300000896622srt:NorthAmericaMemberatr:AptarBeautyMember2024-07-012024-09-300000896622srt:LatinAmericaMemberatr:AptarBeautyMember2024-07-012024-09-300000896622srt:AsiaMemberatr:AptarBeautyMember2024-07-012024-09-300000896622atr:AptarBeautyMember2024-07-012024-09-300000896622srt:EuropeMemberatr:AptarClosuresMember2024-07-012024-09-300000896622srt:NorthAmericaMemberatr:AptarClosuresMember2024-07-012024-09-300000896622srt:LatinAmericaMemberatr:AptarClosuresMember2024-07-012024-09-300000896622srt:AsiaMemberatr:AptarClosuresMember2024-07-012024-09-300000896622atr:AptarClosuresMember2024-07-012024-09-300000896622srt:EuropeMember2024-07-012024-09-300000896622srt:NorthAmericaMember2024-07-012024-09-300000896622srt:LatinAmericaMember2024-07-012024-09-300000896622srt:AsiaMember2024-07-012024-09-300000896622srt:EuropeMemberatr:AptarPharmaMember2023-07-012023-09-300000896622srt:NorthAmericaMemberatr:AptarPharmaMember2023-07-012023-09-300000896622srt:LatinAmericaMemberatr:AptarPharmaMember2023-07-012023-09-300000896622srt:AsiaMemberatr:AptarPharmaMember2023-07-012023-09-300000896622atr:AptarPharmaMember2023-07-012023-09-300000896622srt:EuropeMemberatr:AptarBeautyMember2023-07-012023-09-300000896622srt:NorthAmericaMemberatr:AptarBeautyMember2023-07-012023-09-300000896622srt:LatinAmericaMemberatr:AptarBeautyMember2023-07-012023-09-300000896622srt:AsiaMemberatr:AptarBeautyMember2023-07-012023-09-300000896622atr:AptarBeautyMember2023-07-012023-09-300000896622srt:EuropeMemberatr:AptarClosuresMember2023-07-012023-09-300000896622srt:NorthAmericaMemberatr:AptarClosuresMember2023-07-012023-09-300000896622srt:LatinAmericaMemberatr:AptarClosuresMember2023-07-012023-09-300000896622srt:AsiaMemberatr:AptarClosuresMember2023-07-012023-09-300000896622atr:AptarClosuresMember2023-07-012023-09-300000896622srt:EuropeMember2023-07-012023-09-300000896622srt:NorthAmericaMember2023-07-012023-09-300000896622srt:LatinAmericaMember2023-07-012023-09-300000896622srt:AsiaMember2023-07-012023-09-300000896622srt:EuropeMemberatr:AptarPharmaMember2024-01-012024-09-300000896622srt:NorthAmericaMemberatr:AptarPharmaMember2024-01-012024-09-300000896622srt:LatinAmericaMemberatr:AptarPharmaMember2024-01-012024-09-300000896622srt:AsiaMemberatr:AptarPharmaMember2024-01-012024-09-300000896622atr:AptarPharmaMember2024-01-012024-09-300000896622srt:EuropeMemberatr:AptarBeautyMember2024-01-012024-09-300000896622srt:NorthAmericaMemberatr:AptarBeautyMember2024-01-012024-09-300000896622srt:LatinAmericaMemberatr:AptarBeautyMember2024-01-012024-09-300000896622srt:AsiaMemberatr:AptarBeautyMember2024-01-012024-09-300000896622atr:AptarBeautyMember2024-01-012024-09-300000896622srt:EuropeMemberatr:AptarClosuresMember2024-01-012024-09-300000896622srt:NorthAmericaMemberatr:AptarClosuresMember2024-01-012024-09-300000896622srt:LatinAmericaMemberatr:AptarClosuresMember2024-01-012024-09-300000896622srt:AsiaMemberatr:AptarClosuresMember2024-01-012024-09-300000896622atr:AptarClosuresMember2024-01-012024-09-300000896622srt:EuropeMember2024-01-012024-09-300000896622srt:NorthAmericaMember2024-01-012024-09-300000896622srt:LatinAmericaMember2024-01-012024-09-300000896622srt:AsiaMember2024-01-012024-09-300000896622srt:EuropeMemberatr:AptarPharmaMember2023-01-012023-09-300000896622srt:NorthAmericaMemberatr:AptarPharmaMember2023-01-012023-09-300000896622srt:LatinAmericaMemberatr:AptarPharmaMember2023-01-012023-09-300000896622srt:AsiaMemberatr:AptarPharmaMember2023-01-012023-09-300000896622atr:AptarPharmaMember2023-01-012023-09-300000896622srt:EuropeMemberatr:AptarBeautyMember2023-01-012023-09-300000896622srt:NorthAmericaMemberatr:AptarBeautyMember2023-01-012023-09-300000896622srt:LatinAmericaMemberatr:AptarBeautyMember2023-01-012023-09-300000896622srt:AsiaMemberatr:AptarBeautyMember2023-01-012023-09-300000896622atr:AptarBeautyMember2023-01-012023-09-300000896622srt:EuropeMemberatr:AptarClosuresMember2023-01-012023-09-300000896622srt:NorthAmericaMemberatr:AptarClosuresMember2023-01-012023-09-300000896622srt:LatinAmericaMemberatr:AptarClosuresMember2023-01-012023-09-300000896622srt:AsiaMemberatr:AptarClosuresMember2023-01-012023-09-300000896622atr:AptarClosuresMember2023-01-012023-09-300000896622srt:EuropeMember2023-01-012023-09-300000896622srt:NorthAmericaMember2023-01-012023-09-300000896622srt:LatinAmericaMember2023-01-012023-09-300000896622srt:AsiaMember2023-01-012023-09-300000896622us-gaap:OperatingSegmentsMemberatr:AptarPharmaMember2023-12-310000896622us-gaap:OperatingSegmentsMemberatr:AptarBeautyMember2023-12-310000896622us-gaap:OperatingSegmentsMemberatr:AptarClosuresMember2023-12-310000896622us-gaap:OperatingSegmentsMemberatr:AptarPharmaMember2024-01-012024-09-300000896622us-gaap:OperatingSegmentsMemberatr:AptarBeautyMember2024-01-012024-09-300000896622us-gaap:OperatingSegmentsMemberatr:AptarClosuresMember2024-01-012024-09-300000896622us-gaap:OperatingSegmentsMemberatr:AptarPharmaMember2024-09-300000896622us-gaap:OperatingSegmentsMemberatr:AptarBeautyMember2024-09-300000896622us-gaap:OperatingSegmentsMemberatr:AptarClosuresMember2024-09-300000896622us-gaap:PatentsMembersrt:WeightedAverageMember2024-09-300000896622us-gaap:PatentsMember2024-09-300000896622us-gaap:PatentsMember2023-12-310000896622us-gaap:PatentedTechnologyMembersrt:WeightedAverageMember2024-09-300000896622us-gaap:PatentedTechnologyMember2024-09-300000896622us-gaap:PatentedTechnologyMember2023-12-310000896622us-gaap:CustomerRelationshipsMembersrt:WeightedAverageMember2024-09-300000896622us-gaap:CustomerRelationshipsMember2024-09-300000896622us-gaap:CustomerRelationshipsMember2023-12-310000896622us-gaap:TrademarksAndTradeNamesMembersrt:WeightedAverageMember2024-09-300000896622us-gaap:TrademarksAndTradeNamesMember2024-09-300000896622us-gaap:TrademarksAndTradeNamesMember2023-12-310000896622atr:LicensingAgreementsAndOtherProductMembersrt:WeightedAverageMember2024-09-300000896622atr:LicensingAgreementsAndOtherProductMember2024-09-300000896622atr:LicensingAgreementsAndOtherProductMember2023-12-310000896622srt:WeightedAverageMember2024-09-300000896622us-gaap:LineOfCreditMember2024-09-300000896622us-gaap:LineOfCreditMember2023-12-310000896622us-gaap:BankOverdraftsMember2024-09-300000896622us-gaap:BankOverdraftsMember2023-12-310000896622atr:AmendedRevolvingCreditFacilityMaturingInJune2026Member2024-07-010000896622atr:AmendedRevolvingCreditFacilityMaturingInJuly2029Member2024-07-020000896622atr:AmendedRevolvingCreditFacilityMaturingInJuly2029Member2024-07-022024-07-020000896622atr:AmendedRevolvingCreditFacilityMaturingInJuly2029Member2023-12-310000896622atr:AmendedRevolvingCreditFacilityMaturingInJuly2029Memberus-gaap:RevolvingCreditFacilityMember2023-12-310000896622atr:AmendedRevolvingCreditFacilityMaturingInJuly2029Membersrt:SubsidiariesMember2023-12-310000896622atr:AmendedRevolvingCreditFacilityMaturingInJuly2029Memberus-gaap:RevolvingCreditFacilityMember2024-09-300000896622atr:AmendedRevolvingCreditFacilityMaturingInJuly2029Membersrt:SubsidiariesMember2024-09-300000896622atr:TermLoan6.4PercentFloatingDueIn2027Member2024-07-020000896622atr:TermLoan6.4PercentFloatingDueIn2027Member2024-09-300000896622atr:AmendedRevolvingCreditFacilityMaturingInJuly2029Member2024-09-300000896622us-gaap:CommercialPaperMember2024-09-300000896622us-gaap:CommercialPaperMember2023-12-310000896622atr:SeniorUnsecuredNotes3.49PercentDueIn2024Member2024-02-262024-02-260000896622atr:SeniorUnsecuredNotes3.49PercentDueIn2024Member2024-02-260000896622atr:SeniorUnsecuredNotes1.17PercentDueIn2024Member2024-07-192024-07-190000896622atr:SeniorUnsecuredNotes1.17PercentDueIn2024Member2024-07-190000896622atr:SeniorUnsecuredNotes3.4PercentDueInSeptember2024Member2024-09-052024-09-050000896622atr:SeniorUnsecuredNotes3.4PercentDueInSeptember2024Member2024-09-050000896622atr:NotesPayable0.102.25DueInstallmentsThrough2031Membersrt:MinimumMember2024-09-300000896622atr:NotesPayable0.102.25DueInstallmentsThrough2031Membersrt:MaximumMember2024-09-300000896622atr:NotesPayable0.102.25DueInstallmentsThrough2031Member2024-09-300000896622atr:NotesPayable0.102.25DueInstallmentsThrough2031Member2023-12-310000896622atr:SeniorUnsecuredNotes34PercentDueIn2024Member2024-09-300000896622atr:SeniorUnsecuredNotes34PercentDueIn2024Member2023-12-310000896622atr:SeniorUnsecuredNotes35PercentDueIn2024Member2024-09-300000896622atr:SeniorUnsecuredNotes35PercentDueIn2024Member2023-12-310000896622atr:SeniorUnsecuredNotes1.2PercentDueIn2024Member2024-09-300000896622atr:SeniorUnsecuredNotes1.2PercentDueIn2024Member2023-12-310000896622atr:SeniorUnsecuredNotes36PercentDueIn2025Member2024-09-300000896622atr:SeniorUnsecuredNotes36PercentDueIn2025Member2023-12-310000896622atr:SeniorUnsecuredNotes36PercentDueIn2026Member2024-09-300000896622atr:SeniorUnsecuredNotes36PercentDueIn2026Member2023-12-310000896622atr:TermLoan6.4PercentFloatingDueIn2027Member2023-12-310000896622atr:SeniorUnsecuredNotes36PercentDueIn2032Member2024-09-300000896622atr:SeniorUnsecuredNotes36PercentDueIn2032Member2023-12-310000896622srt:MaximumMember2024-09-300000896622srt:MinimumMember2024-09-300000896622country:US2024-07-012024-09-300000896622country:US2023-07-012023-09-300000896622us-gaap:ForeignPlanMember2024-07-012024-09-300000896622us-gaap:ForeignPlanMember2023-07-012023-09-300000896622country:US2024-01-012024-09-300000896622country:US2023-01-012023-09-300000896622us-gaap:ForeignPlanMember2024-01-012024-09-300000896622us-gaap:ForeignPlanMember2023-01-012023-09-300000896622us-gaap:AccumulatedTranslationAdjustmentMember2022-12-310000896622us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-12-310000896622us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-12-310000896622us-gaap:AccumulatedTranslationAdjustmentMember2023-01-012023-09-300000896622us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-01-012023-09-300000896622us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-01-012023-09-300000896622us-gaap:AccumulatedTranslationAdjustmentMember2023-09-300000896622us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-09-300000896622us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-09-300000896622us-gaap:AccumulatedTranslationAdjustmentMember2023-12-310000896622us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-12-310000896622us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-12-310000896622us-gaap:AccumulatedTranslationAdjustmentMember2024-01-012024-09-300000896622us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-01-012024-09-300000896622us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-01-012024-09-300000896622us-gaap:AccumulatedTranslationAdjustmentMember2024-09-300000896622us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-09-300000896622us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-09-300000896622us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300000896622us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300000896622us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300000896622us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300000896622us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-01-012024-09-300000896622us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300000896622us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-01-012024-09-300000896622us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300000896622us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMember2022-07-062022-07-060000896622us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMember2022-07-060000896622atr:SeniorUnsecuredNotes36PercentDueIn2032Member2022-07-060000896622atr:SeniorUnsecuredNotes36PercentDueIn2032Member2022-07-062022-07-060000896622us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMember2024-09-300000896622us-gaap:ForeignExchangeContractMemberus-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2024-09-300000896622us-gaap:ForeignExchangeContractMemberus-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMember2024-09-300000896622us-gaap:ForeignExchangeContractMember2024-09-300000896622us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2024-09-300000896622us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2023-12-310000896622us-gaap:ForeignExchangeContractMemberus-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2023-12-310000896622us-gaap:DesignatedAsHedgingInstrumentMember2024-09-300000896622us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember2024-09-300000896622us-gaap:DesignatedAsHedgingInstrumentMember2023-12-310000896622us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember2023-12-310000896622us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMember2024-09-300000896622us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMember2023-12-310000896622us-gaap:ForeignExchangeContractMemberus-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMember2023-12-310000896622us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMember2024-09-300000896622us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMember2024-09-300000896622us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMember2023-12-310000896622us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMember2023-12-310000896622us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:InterestExpenseMember2024-07-012024-09-300000896622us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:InterestExpenseMember2023-07-012023-09-300000896622us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2024-07-012024-09-300000896622us-gaap:CurrencySwapMemberus-gaap:CashFlowHedgingMemberus-gaap:OtherNonoperatingIncomeExpenseMember2024-07-012024-09-300000896622us-gaap:CurrencySwapMemberus-gaap:CashFlowHedgingMemberus-gaap:OtherNonoperatingIncomeExpenseMember2023-07-012023-09-300000896622us-gaap:CurrencySwapMemberus-gaap:CashFlowHedgingMember2024-07-012024-09-300000896622us-gaap:CashFlowHedgingMember2024-07-012024-09-300000896622us-gaap:CashFlowHedgingMember2023-07-012023-09-300000896622us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:InterestExpenseMember2024-01-012024-09-300000896622us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:InterestExpenseMember2023-01-012023-09-300000896622us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2024-01-012024-09-300000896622us-gaap:CurrencySwapMemberus-gaap:CashFlowHedgingMemberus-gaap:OtherNonoperatingIncomeExpenseMember2024-01-012024-09-300000896622us-gaap:CurrencySwapMemberus-gaap:CashFlowHedgingMemberus-gaap:OtherNonoperatingIncomeExpenseMember2023-01-012023-09-300000896622us-gaap:CurrencySwapMemberus-gaap:CashFlowHedgingMember2024-01-012024-09-300000896622us-gaap:CashFlowHedgingMember2024-01-012024-09-300000896622us-gaap:CashFlowHedgingMember2023-01-012023-09-300000896622us-gaap:ForeignExchangeContractMember2024-07-012024-09-300000896622us-gaap:ForeignExchangeContractMember2023-07-012023-09-300000896622us-gaap:ForeignExchangeContractMember2024-01-012024-09-300000896622us-gaap:ForeignExchangeContractMember2023-01-012023-09-300000896622us-gaap:FairValueMeasurementsRecurringMember2024-09-300000896622us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300000896622us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300000896622us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300000896622us-gaap:FairValueMeasurementsRecurringMember2023-12-310000896622us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000896622us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000896622us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000896622us-gaap:IndemnificationGuaranteeMember2024-09-300000896622us-gaap:IndemnificationGuaranteeMember2023-12-310000896622atr:TaxAssessmentMember2024-09-300000896622atr:TaxAssessmentInterestAndPenaltiesMembersrt:MinimumMember2024-09-300000896622atr:TaxAssessmentInterestAndPenaltiesMembersrt:MaximumMember2024-09-300000896622atr:StockRepurchaseProgramApril182019Member2019-04-180000896622atr:StockRepurchaseProgramOctober102024Memberus-gaap:SubsequentEventMember2024-10-100000896622atr:RestrictedStockUnitsTimeBasedMember2024-01-012024-09-300000896622atr:RestrictedStockUnitsPerformanceBasedMember2024-01-012024-09-300000896622atr:RestrictedStockUnitsPerformanceBasedMember2023-01-012023-09-300000896622atr:RestrictedStockUnitsTimeBasedMember2023-12-310000896622atr:RestrictedStockUnitsPerformanceBasedMember2023-12-310000896622atr:RestrictedStockUnitsTimeBasedMember2024-09-300000896622atr:RestrictedStockUnitsPerformanceBasedMember2024-09-300000896622atr:RestrictedStockUnitsTimeBasedMemberatr:DirectorStockOptionPlansMember2024-01-012024-09-300000896622us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-300000896622us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-300000896622us-gaap:RestrictedStockUnitsRSUMember2024-09-300000896622us-gaap:EmployeeStockOptionMember2024-01-012024-09-300000896622srt:ExecutiveOfficerMember2023-01-012023-09-300000896622atr:NonExecutiveOfficerEmployeesMember2023-01-012023-09-300000896622us-gaap:EmployeeStockOptionMemberatr:StockAwardPlansMember2024-01-012024-09-300000896622us-gaap:EmployeeStockOptionMemberatr:StockAwardPlansMember2023-01-012023-09-300000896622us-gaap:EmployeeStockOptionMemberatr:StockAwardPlansMember2023-12-310000896622us-gaap:EmployeeStockOptionMemberatr:DirectorStockOptionPlansMember2023-12-310000896622us-gaap:EmployeeStockOptionMemberatr:DirectorStockOptionPlansMember2024-01-012024-09-300000896622us-gaap:EmployeeStockOptionMemberatr:StockAwardPlansMember2024-09-300000896622us-gaap:EmployeeStockOptionMemberatr:DirectorStockOptionPlansMember2024-09-300000896622us-gaap:EmployeeStockOptionMemberatr:DirectorStockOptionPlansMember2023-01-012023-09-300000896622us-gaap:EmployeeStockOptionMemberatr:SellingResearchAndDevelopmentAndAdministrativeExpensesMember2024-01-012024-09-300000896622us-gaap:EmployeeStockOptionMemberatr:SellingResearchAndDevelopmentAndAdministrativeExpensesMember2023-01-012023-09-300000896622us-gaap:EmployeeStockOptionMemberus-gaap:CostOfSalesMember2024-01-012024-09-300000896622us-gaap:EmployeeStockOptionMemberus-gaap:CostOfSalesMember2023-01-012023-09-300000896622us-gaap:EmployeeStockOptionMember2023-01-012023-09-300000896622us-gaap:EmployeeStockOptionMember2024-09-300000896622us-gaap:EmployeeStockOptionMember2024-07-012024-09-300000896622us-gaap:EmployeeStockOptionMember2023-07-012023-09-300000896622us-gaap:RestrictedStockUnitsRSUMember2024-07-012024-09-300000896622us-gaap:RestrictedStockUnitsRSUMember2023-07-012023-09-300000896622us-gaap:OperatingSegmentsMemberatr:AptarPharmaMember2024-07-012024-09-300000896622us-gaap:OperatingSegmentsMemberatr:AptarPharmaMember2023-07-012023-09-300000896622us-gaap:OperatingSegmentsMemberatr:AptarPharmaMember2023-01-012023-09-300000896622us-gaap:OperatingSegmentsMemberatr:AptarBeautyMember2024-07-012024-09-300000896622us-gaap:OperatingSegmentsMemberatr:AptarBeautyMember2023-07-012023-09-300000896622us-gaap:OperatingSegmentsMemberatr:AptarBeautyMember2023-01-012023-09-300000896622us-gaap:OperatingSegmentsMemberatr:AptarClosuresMember2024-07-012024-09-300000896622us-gaap:OperatingSegmentsMemberatr:AptarClosuresMember2023-07-012023-09-300000896622us-gaap:OperatingSegmentsMemberatr:AptarClosuresMember2023-01-012023-09-300000896622us-gaap:OperatingSegmentsMember2024-07-012024-09-300000896622us-gaap:OperatingSegmentsMember2023-07-012023-09-300000896622us-gaap:OperatingSegmentsMember2024-01-012024-09-300000896622us-gaap:OperatingSegmentsMember2023-01-012023-09-300000896622us-gaap:IntersegmentEliminationMemberatr:AptarPharmaMember2024-07-012024-09-300000896622us-gaap:IntersegmentEliminationMemberatr:AptarPharmaMember2023-07-012023-09-300000896622us-gaap:IntersegmentEliminationMemberatr:AptarPharmaMember2024-01-012024-09-300000896622us-gaap:IntersegmentEliminationMemberatr:AptarPharmaMember2023-01-012023-09-300000896622us-gaap:IntersegmentEliminationMemberatr:AptarBeautyMember2024-07-012024-09-300000896622us-gaap:IntersegmentEliminationMemberatr:AptarBeautyMember2023-07-012023-09-300000896622us-gaap:IntersegmentEliminationMemberatr:AptarBeautyMember2024-01-012024-09-300000896622us-gaap:IntersegmentEliminationMemberatr:AptarBeautyMember2023-01-012023-09-300000896622us-gaap:IntersegmentEliminationMemberatr:AptarClosuresMember2024-07-012024-09-300000896622us-gaap:IntersegmentEliminationMemberatr:AptarClosuresMember2023-07-012023-09-300000896622us-gaap:IntersegmentEliminationMemberatr:AptarClosuresMember2024-01-012024-09-300000896622us-gaap:IntersegmentEliminationMemberatr:AptarClosuresMember2023-01-012023-09-300000896622us-gaap:IntersegmentEliminationMember2024-07-012024-09-300000896622us-gaap:IntersegmentEliminationMember2023-07-012023-09-300000896622us-gaap:IntersegmentEliminationMember2024-01-012024-09-300000896622us-gaap:IntersegmentEliminationMember2023-01-012023-09-300000896622us-gaap:CorporateNonSegmentMember2024-07-012024-09-300000896622us-gaap:CorporateNonSegmentMember2023-07-012023-09-300000896622us-gaap:CorporateNonSegmentMember2024-01-012024-09-300000896622us-gaap:CorporateNonSegmentMember2023-01-012023-09-300000896622atr:OptimizationInitiativeMember2024-07-012024-09-300000896622atr:OptimizationInitiativeMember2023-07-012023-09-300000896622atr:OptimizationInitiativeMember2024-01-012024-09-300000896622atr:OptimizationInitiativeMember2023-01-012023-09-300000896622atr:PriorYearInitiativesMember2024-07-012024-09-300000896622atr:PriorYearInitiativesMember2023-07-012023-09-300000896622atr:PriorYearInitiativesMember2024-01-012024-09-300000896622atr:PriorYearInitiativesMember2023-01-012023-09-300000896622atr:HengyuAcquisitionMember2023-08-012023-08-010000896622atr:IDSCENTMember2023-03-012023-03-010000896622atr:IDSCENTMember2023-03-010000896622atr:GulfClosuresMember2023-03-010000896622atr:GulfClosuresMember2023-03-012023-03-010000896622atr:BtyMember2024-09-300000896622atr:BtyMember2023-12-310000896622atr:SonmolMember2024-09-300000896622atr:SonmolMember2023-12-310000896622atr:DesotecGmbhMember2024-09-300000896622atr:DesotecGmbhMember2023-12-310000896622atr:PureCycleMember2024-09-300000896622atr:PureCycleMember2023-12-310000896622atr:YATMember2024-09-300000896622atr:YATMember2023-12-310000896622atr:LoopMember2024-09-300000896622atr:LoopMember2023-12-310000896622atr:OthersMember2024-09-300000896622atr:OthersMember2023-12-310000896622atr:NingboJinyuTechnologyIndustryCoLtdMemberus-gaap:SubsequentEventMember2024-10-220000896622atr:NingboJinyuTechnologyIndustryCoLtdMemberus-gaap:SubsequentEventMember2024-10-222024-10-220000896622atr:BtyMember2020-01-010000896622atr:BtyMember2020-01-012020-01-010000896622atr:BtyMemberus-gaap:CallOptionMembersrt:MinimumMember2020-01-010000896622atr:BtyMemberus-gaap:CallOptionMembersrt:MaximumMember2020-01-010000896622atr:BtyMember2024-01-012024-09-300000896622atr:BtyMember2023-01-012023-09-300000896622atr:SonmolMember2020-04-012020-04-010000896622atr:SonmolMember2020-04-010000896622atr:DesotecGmbhMember2009-01-012009-12-310000896622atr:DesotecGmbhMember2009-12-310000896622atr:LoopMemberus-gaap:PreferredStockMember2019-01-012023-12-310000896622atr:PureCycleMemberus-gaap:PreferredStockMember2019-01-012023-12-310000896622atr:PureCycleMember2021-03-310000896622atr:PureCycleMemberus-gaap:PreferredStockMember2021-01-012021-12-310000896622atr:PureCycleMemberus-gaap:PreferredStockMember2022-01-012022-12-310000896622atr:PureCycleMemberus-gaap:PreferredStockMember2023-01-012023-12-310000896622atr:PureCycleMemberus-gaap:PreferredStockMember2024-04-262024-04-260000896622atr:PureCycleMemberus-gaap:PreferredStockMember2024-07-012024-09-300000896622atr:PureCycleMemberus-gaap:PreferredStockMember2023-07-012023-09-300000896622atr:PureCycleMemberus-gaap:PreferredStockMember2024-01-012024-09-300000896622atr:PureCycleMemberus-gaap:PreferredStockMember2023-01-012023-09-300000896622atr:YATMember2021-07-072021-07-070000896622atr:YATMember2021-07-070000896622atr:OptimizationPlanMember2024-07-012024-09-300000896622atr:OptimizationPlanMember2024-01-012024-09-300000896622atr:OptimizationPlanMember2023-07-012023-09-300000896622atr:OptimizationPlanMember2023-01-012023-09-300000896622atr:OptimizationPlanMember2024-09-300000896622us-gaap:EmployeeSeveranceMemberatr:OptimizationPlanMember2023-12-310000896622us-gaap:EmployeeSeveranceMemberatr:OptimizationPlanMember2024-01-012024-09-300000896622us-gaap:EmployeeSeveranceMemberatr:OptimizationPlanMember2024-09-300000896622atr:OtherRestructuringCostsMemberatr:OptimizationPlanMember2023-12-310000896622atr:OtherRestructuringCostsMemberatr:OptimizationPlanMember2024-01-012024-09-300000896622atr:OtherRestructuringCostsMemberatr:OptimizationPlanMember2024-09-300000896622atr:OptimizationPlanMember2023-12-31
目錄
美國
證券交易委員會
華盛頓特區20549
表格10-Q
☒ 根據1934年證券交易法第13或15(d)條，本季度報告
截至2021年6月30日的季度報告 2024年9月30日
或者
☐ 根據1934年證券交易法第13或15（d)條的轉型報告
過渡期從     致：      
委託文件編號 1-11846
atr-20200630x10q002.jpg
AptarGroup, Inc.
特拉華州36-3853103
（擬定公司）（納稅人識別號碼）
交易所大道265號, 301號套房, 水晶湖, 伊利諾伊州 60014
815-477-0424
在法案第12(b)條的規定下注冊的證券：
每一類的名稱交易標的在其上註冊的交易所的名稱
普通股，面值爲0.01美元ATR請使用moomoo賬號登錄查看New York Stock Exchange
請勾選以下項目：（1）報名者是否在過去12個月（或報名者要求提交這些報告的較短期間內）已提交應按1934年證券交易法第13條或第15(d)條提交的所有報告；及（2）報名者是否在過去90天內一直有該項提交要求。是 þ否◻
勾選此項表示申報人在過去12個月內（或者申報人需要提交此類文件的更短時期內）已經準時提交了根據第405條規則和本章節232.405規定要求提交的所有互動數據文件。 是 þ否◻
請勾選指標，以確定註冊者是否爲大型加速申報人、加速申報人、非加速申報人、小型報告公司或新興增長性公司。 請參閱交易所法規120億.2中「大型加速申報人」、「加速申報人」、「小型報告公司」和「新興增長性企業」的定義。
大型加速報告人 ☑
加速文件提交人

☐非加速提交者
filer 		☐較小的報告公司
公司 		☐新興成長公司 ☐
如果是新興成長型企業，請勾選複選標記，表明註冊者已選擇不使用延長過渡期來符合根據證券交易法第13(a)條規定提供的任何新財務會計準則。 ◻
請在以下方框內打勾：公司是否是空殼公司(根據證券交易法第12b-2條規定定義）。是☐否þ
截至2024年10月21日，普通股的流通股數量爲 66,543,252股份。

目錄
愛必達集團，公司
表10-Q
2024年9月30日季度結束
指數
三項相關收入彙總報表 – 三項及 有九起類似訴訟針對JAVELIN的要約收購和合並被提起，稱違反信託責任，尋求公正補償，包括但不限於，禁止交易的達成、撤銷、解除已經交易的事項，以及發送費用、補貼成本，包括合理的律師費和費用。唯一的佛羅里達州訴訟從未向被告送達，該案件於2017年1月20日自願撤回並關閉。2016年4月25日，馬里蘭法院頒佈了一項命令，將馬里蘭案件合併成一起訴訟，標題爲JAVELIN Mortgage Investment Corp.股東訴訟（案號24-C-16-001542），並指定一個馬里蘭案件的律師作爲臨時首席聯合法律顧問。2016年5月26日，臨時首席律師提交了經修訂的釩化鐵質量投訴，聲稱違反信託責任的集體索賠，教唆和共謀違反信託責任以及浪費。2016年6月27日，被告提出了駁回合併修訂集體投訴申請的動議，聲稱未陳述可以獲得救濟的規定。在2017年3月3日，聽證會召開了駁回動議，法院保留了裁定。法院數次推遲動議陳述的裁定。2024年2月14日，法院頒佈裁定，支持被告的駁回動議，並駁回所有原告的權利，無需上訴。在2024年3月11日，原告提出了對法院裁定的上訴通知。2024年7月3日，原告自願撤回之前提出的上訴通知。 和202 九月 30、2024和2023年
綜合收益簡表-三個 有九起類似訴訟針對JAVELIN的要約收購和合並被提起，稱違反信託責任，尋求公正補償，包括但不限於，禁止交易的達成、撤銷、解除已經交易的事項，以及發送費用、補貼成本，包括合理的律師費和費用。唯一的佛羅里達州訴訟從未向被告送達，該案件於2017年1月20日自願撤回並關閉。2016年4月25日，馬里蘭法院頒佈了一項命令，將馬里蘭案件合併成一起訴訟，標題爲JAVELIN Mortgage Investment Corp.股東訴訟（案號24-C-16-001542），並指定一個馬里蘭案件的律師作爲臨時首席聯合法律顧問。2016年5月26日，臨時首席律師提交了經修訂的釩化鐵質量投訴，聲稱違反信託責任的集體索賠，教唆和共謀違反信託責任以及浪費。2016年6月27日，被告提出了駁回合併修訂集體投訴申請的動議，聲稱未陳述可以獲得救濟的規定。在2017年3月3日，聽證會召開了駁回動議，法院保留了裁定。法院數次推遲動議陳述的裁定。2024年2月14日，法院頒佈裁定，支持被告的駁回動議，並駁回所有原告的權利，無需上訴。在2024年3月11日，原告提出了對法院裁定的上訴通知。2024年7月3日，原告自願撤回之前提出的上訴通知。 和202 九月 30、2024和2023年
控件綜合變動情況表 – 三和 有九起類似訴訟針對JAVELIN的要約收購和合並被提起，稱違反信託責任，尋求公正補償，包括但不限於，禁止交易的達成、撤銷、解除已經交易的事項，以及發送費用、補貼成本，包括合理的律師費和費用。唯一的佛羅里達州訴訟從未向被告送達，該案件於2017年1月20日自願撤回並關閉。2016年4月25日，馬里蘭法院頒佈了一項命令，將馬里蘭案件合併成一起訴訟，標題爲JAVELIN Mortgage Investment Corp.股東訴訟（案號24-C-16-001542），並指定一個馬里蘭案件的律師作爲臨時首席聯合法律顧問。2016年5月26日，臨時首席律師提交了經修訂的釩化鐵質量投訴，聲稱違反信託責任的集體索賠，教唆和共謀違反信託責任以及浪費。2016年6月27日，被告提出了駁回合併修訂集體投訴申請的動議，聲稱未陳述可以獲得救濟的規定。在2017年3月3日，聽證會召開了駁回動議，法院保留了裁定。法院數次推遲動議陳述的裁定。2024年2月14日，法院頒佈裁定，支持被告的駁回動議，並駁回所有原告的權利，無需上訴。在2024年3月11日，原告提出了對法院裁定的上訴通知。2024年7月3日，原告自願撤回之前提出的上訴通知。 和202 九月 30、2024和2023年
i
目錄
第一部分-財務信息
項目1.基本報表（未經審計）
愛必達集團，公司
簡明合併利潤表
(未經審計)
以千爲單位，除每股數以外的貨幣金額
三個月之內結束
2020年9月30日		九個月結束
2020年9月30日
2024202320242023
淨銷售額$909,291 $892,997 $2,734,802 $2,648,970 
營業費用：
銷售成本（不包括下面顯示的折舊和攤銷）558,511 566,691 1,708,707 1,697,824 
銷售、研究與開發和行政管理141,604 138,137 443,714 427,488 
折舊和攤銷67,015 62,686 196,332 184,212 
重組計劃3,864 6,161 9,659 19,628 
總營業費用770,994 773,675 2,358,412 2,329,152 
營業收入138,297 119,322 376,390 319,818 
其他（支出）收入：
利息支出(12,290)(9,984)(32,526)(29,900)
利息收入3,022 946 9,022 2,266 
淨投資損益1,043 (1,240)1,495 1,839 
關聯公司業績中的股權(77)1,002 (168)1,514 
雜項收益（費用），淨額1,136 3 (518)(1,341)
其他總支出(7,166)(9,273)(22,695)(25,622)
稅前收入131,131 110,049 353,695 294,196 
所得稅規定31,209 25,751 80,382 72,265 
淨利潤$99,922 $84,298 $273,313 $221,931 
非控制權益可歸屬的淨損失（收益）$117 $(2)$284 $201 
歸屬於AptarGroup, Inc.的淨利潤$100,039 $84,296 $273,597 $222,132 
每股AptarGroup, Inc.的淨利潤
基本$1.51 $1.28 $4.13 $3.39 
稀釋的$1.48 $1.26 $4.05 $3.32 
平均流通股數：
基本66,445 65,707 66,274 65,550 
稀釋的67,716 67,035 67,574 66,865 
施樂控股公司$0.45 $0.41 $1.27 $1.17 

請參閱未經審計的附註至基本報表。
1
目錄
愛必達集團，公司
綜合收益簡明合併報表
(未經審計)
以千爲單位
三個月之內結束
2020年9月30日		九個月結束
2020年9月30日
2024202320242023
淨利潤$99,922 $84,298 $273,313 $221,931 
其他全面收益（虧損）：
外幣翻譯調整66,736 (52,514)625 (28,639)
衍生工具變動（損失）收益，稅後(5,711)2,707 (202)(2,424)
確定福利養老金計劃，稅後
精算（損失）收益，稅後(634)(5)(532)63 
淨利潤中包括的往前役工資成本攤銷，稅後22 33 62 98 
淨利潤中包括的淨虧損攤銷，稅後214 161 578 483 
淨確定福利養老金計劃，扣除稅金後(398)189 108 644 
其他綜合收益（損失）總額60,627 (49,618)531 (30,419)
綜合收益160,549 34,680 273,844 191,512 
歸屬於非控制股東的綜合（損益）(866)88 (158)319 
歸屬於AptarGroup, Inc.的綜合收益$159,683 $34,768 $273,686 $191,831 
請參閱未經審計的附註至基本報表。
2
目錄
愛必達集團，公司
簡明合併資產負債表
(未經審計)
以千爲單位
2024年9月30日2023年12月31日
資產
現金及現金等價物$325,524 $223,643 
短期投資2,387 — 
應收賬款及應付票據淨額，減去當前預期信用損失（「CECL」）的$14,264的。16,217在2023年被Men's Journal評爲美國排名第一的健身房連鎖店
698,989 677,822 
存貨488,540 513,053 
預付款項及其他150,164 134,761 
流動資產合計1,665,604 1,549,279 
土地29,924 30,090 
建築物和改善776,798 748,897 
機械和設備3,270,657 3,183,097 
房地產、廠房和設備總額4,077,379 3,962,084 
減：累計折舊(2,572,170)(2,484,021)
淨固定資產1,505,209 1,478,063 
股票投資51,052 49,203 
商譽968,293 963,418 
無形資產, 淨額271,215 283,211 
經營租賃權使用資產75,416 59,074 
其他88,426 69,642 
其他資產總額1,454,402 1,424,548 
總資產$4,625,215 $4,451,890 
See accompanying unaudited Notes to Condensed Consolidated Financial Statements.
3
Table of Contents
AptarGroup, Inc.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
In thousands, except share and per share amounts
September 30, 2024December 31, 2023
Liabilities and Stockholders’ Equity
Current Liabilities:
Revolving credit facility and overdrafts
$222,817 $81,794 
Current maturities of long-term obligations, net of unamortized debt issuance costs30,295 376,426 
Accounts payable, accrued and other liabilities773,540 793,089 
Total Current Liabilities1,026,652 1,251,309 
Long-Term Obligations, net of unamortized debt issuance costs822,731 681,188 
Deferred income taxes13,896 19,016 
Retirement and deferred compensation plans71,853 62,795 
Operating lease liabilities58,864 45,267 
Deferred and other non-current liabilities77,578 71,017 
Commitments and contingencies— — 
Total Deferred Liabilities and Other222,191 198,095 
AptarGroup, Inc. stockholders’ equity
Common stock, $.01 par value, 199 million shares authorized, 72.3 million and 71.7 million shares issued as of September 30, 2024 and December 31, 2023, respectively
723 717 
Capital in excess of par value1,107,597 1,044,429 
Retained earnings2,299,540 2,109,816 
Accumulated other comprehensive loss(308,880)(308,734)
Less: Treasury stock at cost, 5.8 million and 5.8 million shares as of September 30, 2024 and December 31, 2023
(559,971)(539,404)
Total AptarGroup, Inc. Stockholders’ Equity2,539,009 2,306,824 
Noncontrolling interests in subsidiaries14,632 14,474 
Total Stockholders’ Equity2,553,641 2,321,298 
Total Liabilities and Stockholders’ Equity$4,625,215 $4,451,890 
See accompanying unaudited Notes to Condensed Consolidated Financial Statements.
4
Table of Contents
AptarGroup, Inc.
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
(Unaudited)

In thousands
Three Months EndedAptarGroup, Inc. Stockholders’ Equity
September 30, 2024 and 2023Retained EarningsAccumulated
Other
Comprehensive (Loss) Income		Common
Stock
Par Value		Treasury
Stock		Capital in
Excess of
Par Value		Non-
Controlling
Interest		Total
Equity
Balance - June 30, 2023$2,017,065 $(321,913)$713 $(526,484)$1,005,007 $14,038 $2,188,426 
Net income 84,296 — — — — 2 84,298 
Foreign currency translation adjustments(1)(52,423)— — — (90)(52,514)
Changes in unrecognized pension gains and related amortization, net of tax— 189 — — — — 189 
Changes in derivative losses, net of tax
— 2,707 — — — — 2,707 
Stock awards and option exercises— — 2 2,114 23,656 — 25,772 
Cash dividends declared on common stock(26,926)— — — — — (26,926)
Treasury stock purchased— — — (8,263)— — (8,263)
Balance - September 30, 2023$2,074,434 $(371,440)$715 $(532,633)$1,028,663 $13,950 $2,213,689 
Balance - June 30, 2024$2,229,377 $(368,524)$721 $(547,685)$1,082,560 $13,766 $2,410,215 
Net income (loss)100,039 — — — — (117)99,922 
Foreign currency translation adjustments— 65,753 — — — 983 66,736 
Changes in unrecognized pension losses and related amortization, net of tax— (398)— — — — (398)
Changes in derivative losses, net of tax— (5,711)— — — — (5,711)
Stock awards and option exercises— — 2 1,883 25,037 — 26,922 
Cash dividends declared on common stock(29,876)— — — — — (29,876)
Treasury stock purchased— — — (14,169)— — (14,169)
Balance - September 30, 2024$2,299,540 $(308,880)$723 $(559,971)$1,107,597 $14,632 $2,553,641 
5
Table of Contents
In thousands
Nine Months EndedAptarGroup, Inc. Stockholders’ Equity
September 30, 2024 and 2023Retained
Earnings		Accumulated
Other
Comprehensive
(Loss) Income		Common
Stock
Par Value		Treasury
Stock		Capital in
Excess of
Par Value		Non-
Controlling
Interest		Total
Equity
Balance - December 31, 2022
$1,929,240 $(341,366)$709 $(503,266)$968,618 $14,269 $2,068,204 
Net income (loss)222,132 — — — — (201)221,931 
Foreign currency translation adjustments(227)(28,294)— — — (118)(28,639)
Changes in unrecognized pension gains and related amortization, net of tax
— 644 — — — — 644 
Changes in derivative losses, net of tax
— (2,424)— — — — (2,424)
Stock awards and option exercises— — 6 7,935 60,045 — 67,986 
Cash dividends declared on common stock(76,711)— — — — — (76,711)
Treasury stock purchased— — — (37,302)— — (37,302)
Balance - September 30, 2023$2,074,434 $(371,440)$715 $(532,633)$1,028,663 $13,950 $2,213,689 
Balance - December 31, 2023
$2,109,816 $(308,734)$717 $(539,404)$1,044,429 $14,474 $2,321,298 
Net income (loss)273,597 — — — — (284)273,313 
Foreign currency translation adjustments235 (52)— — — 442 625 
Changes in unrecognized pension gains and related amortization, net of tax
— 108 — — — — 108 
Changes in derivative losses, net of tax— (202)— — — — (202)
Stock awards and option exercises— — 6 10,736 63,168 — 73,910 
Cash dividends declared on common stock(84,108)— — — — — (84,108)
Treasury stock purchased— — — (31,303)— — (31,303)
Balance - September 30, 2024$2,299,540 $(308,880)$723 $(559,971)$1,107,597 $14,632 $2,553,641 
See accompanying unaudited Notes to Condensed Consolidated Financial Statements.
6
Table of Contents
AptarGroup, Inc.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
In thousands, brackets denote cash outflows
Nine Months Ended September 30,20242023
Cash Flows from Operating Activities:
Net income$273,313 $221,931 
Adjustments to reconcile net income to net cash provided by operations:
Depreciation162,925 150,718 
Amortization33,407 33,494 
Stock-based compensation37,962 36,084 
(Release) provision for CECL
(1,221)3,449 
Gain on disposition of fixed assets(462)(3,753)
Net gain on remeasurement of equity securities(1,495)(1,839)
Deferred income taxes(11,653)(16,978)
Defined benefit plan expense9,296 10,659 
Equity in results of affiliates168 (1,514)
Changes in balance sheet items, excluding effects from foreign currency adjustments:
Accounts and other receivables(24,054)(43,061)
Inventories22,653 (5,188)
Prepaid and other current assets(13,970)(19,236)
Accounts payable, accrued and other liabilities(14,371)3,860 
Income taxes payable6,672 (8,732)
Retirement and deferred compensation plan liabilities(3,832)1,323 
Other changes, net(10,164)(5,615)
Net Cash Provided by Operations465,174 355,602 
Cash Flows from Investing Activities:
Capital expenditures(210,416)(231,199)
Proceeds from sale of property, plant and equipment1,020 6,037 
Maturity of short-term investment(2,242)— 
Acquisition of businesses, net of cash acquired and release of escrow— (16,570)
Acquisition of intangible assets, net(13,242)(3,648)
Proceeds from sale of investment in equity securities— 5,604 
Notes receivable, net(776)439 
Net Cash Used by Investing Activities(225,656)(239,337)
Cash Flows from Financing Activities:
Proceeds from notes payable and overdrafts22,302 24,392 
Repayments of notes payable and overdrafts(23,184)(27,863)
Proceeds and (repayments) of short-term revolving credit facility, net
138,058 123,514 
Proceeds from long-term obligations168,614 257 
Repayments of long-term obligations(372,393)(117,289)
Payment of contingent consideration obligation— (22,750)
Dividends paid(84,108)(76,711)
Proceeds from stock option exercises44,364 39,742 
Purchase of treasury stock(31,303)(37,302)
Net Cash Used by Financing Activities(137,650)(94,010)
Effect of Exchange Rate Changes on Cash13 (12,914)
Net Increase in Cash and Equivalents and Restricted Cash
101,881 9,341 
Cash and Equivalents and Restricted Cash at Beginning of Period223,643 142,732 
Cash and Equivalents and Restricted Cash at End of Period$325,524 $152,073 
7
Table of Contents
Restricted cash included in the line item prepaid and other on the Condensed Consolidated Balance Sheets as shown below represents amounts held in escrow related to the Metaphase acquisition.
Nine Months Ended September 30,20242023
Cash and equivalents$325,524 $151,573 
Restricted cash included in prepaid and other— 500 
Total Cash and Equivalents and Restricted Cash shown in the Statement of Cash Flows$325,524 $152,073 
See accompanying unaudited Notes to Condensed Consolidated Financial Statements.
8
Table of Contents
AptarGroup, Inc.
Notes to Condensed Consolidated Financial Statements
(Dollars in Thousands, Except per Share Amounts, or as Otherwise Indicated)
(Unaudited)
NOTE 1 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
BASIS OF PRESENTATION
The accompanying unaudited Condensed Consolidated Financial Statements include the accounts of AptarGroup, Inc. and our subsidiaries. The terms “AptarGroup,” “Aptar,” “Company,” “we,” “us” or “our” as used herein refer to AptarGroup, Inc. and our subsidiaries. All significant intercompany accounts and transactions have been eliminated. Certain previously reported amounts have been reclassified to conform to the current period presentation.
In the opinion of management, the unaudited Condensed Consolidated Financial Statements (the “Condensed Consolidated Financial Statements”) include all normal recurring adjustments necessary for a fair statement of consolidated financial position, results of operations, comprehensive income, changes in equity and cash flows for the interim periods presented. The accompanying Condensed Consolidated Financial Statements have been prepared by the Company, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations, although we believe that the disclosures made are adequate to make the information presented not misleading. Also, certain financial position data included herein was derived from the audited Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2023 but does not include all disclosures required by U.S. GAAP. Accordingly, these Condensed Consolidated Financial Statements and related notes should be read in conjunction with the audited Consolidated Financial Statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2023. The results of operations of any interim period are not necessarily indicative of the results that may be expected for the year.
ADOPTION OF RECENT ACCOUNTING STANDARDS
Changes to U.S. GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of Accounting Standards Updates (“ASUs”) to the FASB’s Accounting Standards Codification.
In March 2020, the FASB issued ASU 2020-04, which provides optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships and other transactions affected by reference rate reform if certain criteria are met. The amendments to this update apply only to contracts, hedging relationships and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. ASU 2020-04 was further amended in January 2021 by ASU 2021-01 which clarified the applicability of certain provisions. Both standards are effective upon issuance and could be adopted any time prior to December 31, 2022. The guidance in ASU 2020-04 and ASU 2021-01 is optional and may be elected over time as reference rate reform activities occur. We adopted this guidance in the second quarter of 2023 and have transitioned away from the London Interbank Offered Rate (“LIBOR”) to the Secured Overnight Financing Rate (“SOFR”) in our revolving credit facility.
In November 2023, the FASB issued ASU 2023-07, Improvement to Reportable Segment Disclosures, which requires enhanced disclosures about significant segment expenses on an annual and interim basis. The amendments in ASU 2023-07 are effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted, and are to be applied on a retrospective basis. We are evaluating the impact of the standard on our segment reporting disclosures.
In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures, which is intended to improve income tax disclosure requirements by requiring (i) consistent categories and greater disaggregation of information in the rate reconciliation and (ii) the disaggregation of income taxes paid by jurisdiction. The guidance makes several other changes to income tax disclosure requirements. The amendments in ASU 2023-09 are effective for fiscal years beginning after December 15, 2024, with early adoption permitted, and are required to be applied prospectively with the option of retrospective application. We are evaluating the impact of the standard on our income tax disclosures.
Other accounting standards that have been issued by the FASB or other standards-setting bodies did not have a material impact on our Condensed Consolidated Financial Statements.
INCOME TAXES
We compute taxes on income in accordance with the tax rules and regulations of the many taxing authorities where income is earned. The income tax rates imposed by these taxing authorities may vary substantially. Taxable income may differ from pre-tax income for U.S. GAAP financial accounting purposes. To the extent that these differences create temporary differences between the tax basis of an asset or liability and our reported amount in the U.S. GAAP financial statements, an appropriate provision for deferred income taxes is made.
9
Table of Contents
We maintain our assertion that the cash and distributable reserves at our non-U.S. affiliates are indefinitely reinvested with the following exceptions: all earnings in Germany and the pre-2020 earnings in Italy, Switzerland and Colombia. As of September 30, 2024, under currently enacted laws, we do not have a balance of foreign earnings that will be subject to U.S. taxation upon repatriation. We will provide for the necessary withholding and local income taxes when management decides that an affiliate should make a distribution. These decisions are made taking into consideration the financial requirements of the non-U.S. affiliates and our global cash management goals. See Note 5 – Income Taxes for more information.
We provide a liability for the amount of unrecognized tax benefits from uncertain tax positions. This liability is provided whenever we determine that a tax benefit will not meet a more-likely-than-not threshold for recognition.
We are subject to the examination of our returns and other tax matters by the U.S. Internal Revenue Service as well as other tax authorities and governmental bodies. We believe that we have adequately provided a tax reserve for any adjustments that may result from tax examinations or uncertain tax positions. However, the outcome of tax audits cannot be predicted with certainty. If any issues addressed in our tax audits are resolved in a manner inconsistent with its expectations, we could be required to adjust its provision for income taxes in the period such resolution occurs. The resolution of each of these audits is not expected to be material to our Condensed Consolidated Financial Statements.
ASSETS HELD FOR SALE
Assets to be disposed of by sale are reported at the lower of their carrying amount or fair value less costs to sell, and are not depreciated while they are held for sale. During the second quarter of 2023, we recorded $0.7 million as assets held for sale within prepaid and other on our Condensed Consolidated Balance Sheets related to three buildings located in France. During the third quarter of 2023, two of the three buildings were sold and we recognized a $0.8 million gain on sale. As of September 30, 2024, one building is still held for sale and expected to be sold during 2025.
SUPPLY CHAIN FINANCE PROGRAM
We facilitate a supply chain finance program (“SCF”) across Europe and the U.S. that is administered by a third-party platform. Eligible suppliers can elect to receive early payment of invoices, less an interest deduction, and negotiate their receivable sales arrangements through the third-party platform on behalf of the respective SCF bank. We are not a party to those agreements, and the terms of our payment obligations are not impacted by a supplier's participation in the SCF. Accordingly, we have concluded that this program continues to be a trade payable program and is not indicative of a borrowing arrangement. Under these agreements, the average payment terms range from 60 to 120 days and are based on industry standards and best practices within each of our regions.
All outstanding amounts related to suppliers participating in the SCF are recorded within accounts payable, accrued and other liabilities in our Condensed Consolidated Balance Sheets, and associated payments are included in operating activities within our Condensed Consolidated Statements of Cash Flows. As of September 30, 2024, the amounts due to suppliers participating in the SCF and included in accounts payable, accrued and other liabilities were approximately $35.0 million.
Collection and payment periods tend to be longer for our operations located outside the United States due to local business practices. We have also seen an increasing trend in pressure from certain customers to lengthen their payment terms. As the majority of our products are made to order, we have not needed to keep significant amounts of finished goods inventory to meet customer requirements. However, some of our contracts specify an amount of finished goods safety stock we are required to maintain.
To the extent our financial position allows and there is a clear financial benefit, we from time-to-time benefit from early payment discounts with some suppliers. We have lengthened the payment terms with our suppliers to be in line with customer trends. While we have offered a third party alternative for our suppliers to receive payments sooner, we generally do not utilize these offerings from our customers as the economic conditions currently are not beneficial for us.
 
10
Table of Contents
NOTE 2 – REVENUE
In prior years, our geographic revenue disclosure was based on shipped from location. Beginning in 2024, we have started to report our geographic sales based on shipped to locations to give the reader a better understanding of the geographies we serve. Revenue by segment and geography based on shipped to locations for the three and nine months ended September 30, 2024 and 2023 were as follows:
For the Three Months Ended September 30, 2024
SegmentEuropeDomesticLatin
America		AsiaTotal
Aptar Pharma$204,835 $142,747 $10,925 $62,087 $420,594 
Aptar Beauty182,708 59,954 37,565 22,632 302,859 
Aptar Closures57,586 88,870 20,665 18,717 185,838 
Total$445,129 $291,571 $69,155 $103,436 $909,291 
For the Three Months Ended September 30, 2023
SegmentEuropeDomesticLatin
America		AsiaTotal
Aptar Pharma$198,546 $125,730 $13,549 $51,363 $389,188 
Aptar Beauty201,127 55,674 42,497 24,682 323,980 
Aptar Closures55,508 85,612 21,863 16,846 179,829 
Total$455,181 $267,016 $77,909 $92,891 $892,997 
For the Nine Months Ended September 30, 2024
SegmentEuropeDomesticLatin
America		AsiaTotal
Aptar Pharma$624,503 $407,291 $36,848 $173,778 $1,242,420 
Aptar Beauty579,638 189,849 117,959 64,220 951,666 
Aptar Closures165,507 262,154 64,221 48,834 540,716 
Total$1,369,648 $859,294 $219,028 $286,832 $2,734,802 
For the Nine Months Ended September 30, 2023
SegmentEuropeDomesticLatin
America		AsiaTotal
Aptar Pharma$598,728 $354,655 $37,415 $145,136 $1,135,934 
Aptar Beauty622,253 171,602 118,563 67,538 979,956 
Aptar Closures171,645 251,780 63,108 46,547 533,080 
Total$1,392,626 $778,037 $219,086 $259,221 $2,648,970 
We perform our obligations under a contract with a customer by transferring goods and/or services in exchange for consideration from the customer. The timing of performance will sometimes differ from the timing of the invoicing for the associated consideration from the customer, thus resulting in the recognition of a contract asset or a contract liability. We recognize a contract asset when we transfer control of goods or services to a customer prior to invoicing for the related performance obligation. The contract asset is transferred to accounts receivable when the product is shipped and invoiced to the customer. We recognize a contract liability if the customer's payment of consideration precedes the entity's performance.
The opening and closing balances of our contract asset and contract liabilities were as follows:
Balance as of December 31, 2023Balance as of September 30, 2024Increase/
(Decrease)
Contract asset (current)$18,033 $15,000 $(3,033)
Contract liability (current)60,507 64,904 4,397 
Contract liability (long-term)37,756 43,235 5,479 
11
Table of Contents
The differences in the opening and closing balances of our contract asset and contract liabilities are primarily the result of timing differences between our performance and the invoicing. The total amount of revenue recognized during the current year against contract liabilities is $76.5 million, including $40.2 million relating to contract liabilities at the beginning of the year. Current contract assets are included within Prepaid and other, while current contract liabilities and long-term contract liabilities are included within Accounts payable, accrued and other liabilities and Deferred and other non-current liabilities, respectively, within our Condensed Consolidated Balance Sheets.
Determining the Transaction Price
In most cases, the transaction price for each performance obligation is stated in the contract. In determining the variable amounts of consideration within the transaction price (such as volume-based customer rebates), we include an estimate of the expected amount of consideration as revenue. We apply the expected value method based on all of the information (historical, current, and forecast) that is reasonably available and identify reasonable estimates based on this information. We apply the method consistently throughout the contract when estimating the effect of an uncertainty on the amount of variable consideration to which we will be entitled.
Product Sales
We primarily manufacture and sell drug and consumer product dosing, dispensing and protection technologies. The amount of consideration is typically fixed for customers. At the time of delivery, the customer is invoiced at the agreed-upon price. Revenue from product sales is typically recognized upon manufacture or shipment, when control of the goods transfers to the customer.
To determine when the control transfers, we typically assess, among other things, the shipping terms of the contract, shipping being one of the indicators of transfer of control. For a majority of product sales, control of the goods transfers to the customer at the time of shipment of the goods. Once the goods are shipped, we are precluded from redirecting the shipment to another customer. Therefore, our performance obligation is satisfied at the time of shipment. For sales in which control transfers upon delivery, shipping and/or handling costs that occur before the customer obtains control of the goods are deemed to be fulfillment activities and are accounted for as fulfillment costs and revenue is recorded upon final delivery to the customer location. We have elected to account for shipping and handling costs that occur after the customer has obtained control of a good as fulfillment costs rather than as a promised service. We do not have any material significant payment terms as payment is typically received shortly after the point of sale.
There also exist instances where we manufacture highly customized products that have no alternative use to us and for which we have an enforceable right to payment for performance completed to date. For these products, we transfer control and recognize revenue over time by measuring progress towards completion using the output method based on the number of products produced. As we normally make our products to a customer’s order, the time between production and shipment of our products is typically within a few weeks. We believe this measurement provides a faithful depiction of the transfer of goods as the costs incurred reflect the value of the products produced.
As a part of our customary business practice, we offer a standard warranty that the products will materially comply with the technical specifications and will be free from material defects. Because such warranties are not sold separately, do not provide for any service beyond a guarantee of a product’s initial specifications, and are not required by law, there is no revenue deferral for these types of warranties.
Tooling Sales
We also build or contract for molds and other tools (collectively defined as “tooling”) necessary to produce our products. As with product sales, we recognize revenue when control of the tool transfers to the customer. If the tooling is highly customized with no alternative use to us and we have an enforceable right to payment for performance completed to date, we transfer control and recognize revenue over time by measuring progress towards completion using the input method based on costs incurred relative to total estimated costs to completion. Otherwise, revenue for the tooling is recognized at the point in time when the customer approves the tool. We do not have any significant payment terms as payment is typically either received during the mold-build process or shortly after completion.
In certain instances, we offer extended warranties on our tools above and beyond the normal standard warranties. We normally receive payment at the inception of the contract and recognize revenue over the term of the contract. We do not have any material extended warranties as of September 30, 2024 or December 31, 2023.
Service Sales
We also provide services to our customers. As with product sales, we recognize revenue based on completion of each performance obligation of the service contract. Milestone deliverables and upfront payments are tied to specific performance obligations and recognized upon satisfaction of the individual performance obligation.
12
Table of Contents
Royalty Revenue
We determine the amount and timing of royalty revenue based on our contractual agreements with customers. We recognize royalty revenue when earned under the terms of the agreements and when we consider realization of payment to be probable.
Contract Costs
We do not incur significant costs to obtain or fulfill revenue contracts.
Credit Risk
We are exposed to credit losses primarily through our product sales, tooling sales and services to our customers. We assess each customer’s ability to pay for the products we sell by conducting a credit review. The credit review considers our expected billing exposure and timing for payment and the customer’s established credit rating, or our assessment of the customer’s creditworthiness based on our analysis of their financial statements when a credit rating is not available. We also consider contract terms and conditions, country and political risks, and business strategy in our evaluation. A credit limit is established for each customer based on the outcome of this review.
We monitor our ongoing credit exposure through active review of customer balances against contract terms and due dates. Our activities include timely account reconciliation, dispute resolution and payment confirmation. We may employ collection agencies and legal counsel to pursue recovery of defaulted receivables.
NOTE 3 - INVENTORIES
Inventories, by component net of reserves, consisted of:
September 30,
2024		December 31,
2023
Raw materials$140,194 $145,798 
Work in process179,857 176,191 
Finished goods168,489 191,064 
Total$488,540 $513,053 

NOTE 4 – GOODWILL AND OTHER INTANGIBLE ASSETS
The changes in the carrying amount of goodwill for the nine months ended September 30, 2024 by reporting segment were as follows:
Aptar
Pharma		Aptar
Beauty		Aptar ClosuresTotal
Balance as of December 31, 2023$508,447 $287,097 $167,874 $963,418 
Foreign currency exchange effects4,062 986 (173)4,875 
Balance as of September 30, 2024$512,509 $288,083 $167,701 $968,293 
13
Table of Contents
The table below shows a summary of intangible assets as of September 30, 2024 and December 31, 2023.
September 30, 2024December 31, 2023
Weighted Average Amortization Period (Years)Gross
Carrying
Amount		Accumulated
Amortization		Net
Value		Gross
Carrying
Amount		Accumulated
Amortization		Net
Value
Amortized intangible assets:
Patents12.4$18,862 $(2,219)$16,643 $7,362 $(1,754)$5,608 
Acquired technology11.3143,652 (80,584)63,068 142,837 (70,520)72,317 
Customer relationships13.6310,205 (143,613)166,592 308,889 (124,648)184,241 
Trademarks and trade names7.944,187 (36,717)7,470 43,932 (33,368)10,564 
License agreements and other20.326,471 (9,029)17,442 17,213 (6,732)10,481 
Total intangible assets13.3$543,377 $(272,162)$271,215 $520,233 $(237,022)$283,211 
Aggregate amortization expense for the intangible assets above for the quarters ended September 30, 2024 and 2023 was $11,733 and $11,400, respectively. Aggregate amortization expense for the intangible assets above for the nine months ended September 30, 2024 and 2023 was $33,407 and $33,494, respectively.
As of September 30, 2024, future estimated amortization expense for the years ending December 31 is as follows:
2024$11,067 
(remaining estimated amortization for 2024)
202543,616 
202641,540 
202733,354 
202829,203 
Thereafter112,435 
Future amortization expense may fluctuate depending on changes in foreign currency rates. The estimates for amortization expense noted above are based upon foreign exchange rates as of September 30, 2024.
NOTE 5 – INCOME TAXES
The tax provision for interim periods is determined using the estimated annual effective consolidated tax rate, based on the current estimate of full-year earnings and related estimated full year-taxes, adjusted for the impact of discrete quarterly items.
The Organization for Economic Co-operation and Development released Model Global Anti-Base Erosion rules under Pillar Two. Certain countries in which we operate have enacted laws implementing aspects of Pillar Two beginning in 2024. These enacted laws relate to the Pillar Two Income Inclusion Rule and Qualified Domestic Minimum Top-Up Tax with an effective date in 2024. We have analyzed the provisions in the applicable jurisdictions and provided for the appropriate tax amounts. We do not expect a material impact from the implementation of these rules for 2024 but we will continue to monitor future legislations for additional guidance.
The effective tax rate for the three months ended September 30, 2024 and 2023, respectively, was 23.8% and 23.4%. The effective tax rate for the three months ended September 30, 2024 was slightly higher than the same period of 2023 primarily due to an unfavorable mix of earnings forecasted in the second half of 2024.
The effective tax rate for the nine months ended September 30, 2024 and 2023, respectively, was 22.7% and 24.6%. On a nine-month basis, the effective tax rate was lower than the same period of 2023 primarily due to increased tax benefits from share-based compensation and tax incentives in certain non-U.S. jurisdictions for intellectual property development activities.
14
Table of Contents
NOTE 6 – DEBT
Revolving Credit Facility and Overdrafts
At September 30, 2024 and December 31, 2023, our revolving credit facility and overdrafts consisted of the following:
September 30,
2024		December 31,
2023
Revolving credit facility
$222,650 $80,662 
Overdraft
167 1,132 
$222,817 $81,794 
Aptar has a revolving credit facility (the “revolving credit facility”) with a syndicate of banks that provides us with unsecured financing of up to $600 million, which may be increased by up to $300 million more, subject to the satisfaction of certain conditions. The revolving credit facility is available in the U.S. and to our wholly-owned UK subsidiary and could be drawn in various currencies including USD, EUR, GBP, and CHF. The revolving credit facility was set to mature in June 2026, but on July 2, 2024, Aptar entered into a new amended and restated agreement (the “amended revolving credit facility”) that extended the maturity date to July 2029, subject to a maximum of two one-year extensions in certain circumstances, As of December 31, 2023, Aptar had utilized $36.5 million and €40.0 million ($44.2 million) under the revolving credit facility in the U.S. and no balance was utilized by our wholly-owned UK subsidiary. As of September 30, 2024, Aptar had utilized €200 million ($222.7 million) under the amended revolving credit facility in the U.S. and no balance was utilized by our wholly-owned UK subsidiary.
On July 2, 2024, we entered into a term loan with a syndicate of banks (the “Term Loan”). The Term Loan matures in July 2027 and enabled drawings on the loan until September 30, 2024 and provided for unsecured financing of up to $330 million available in the U.S. Funds are to be used to refinance near-term maturities and for general corporate purposes. As of September 30, 2024, $166 million was utilized under the Term Loan facility and the unused portion expired.
There are no compensating balance requirements associated with our amended revolving credit facility. Each borrowing under the amended revolving credit facility will bear interest at rates based on SOFR (in the case of USD), EURIBOR (in the case of EUR), SONIA (in the case of GBP), SARON (in the case of CHF), prime rates or other similar rates, in each case plus an applicable margin. The amended revolving credit facility also provides mechanics relating to a transition away from designated benchmark rates for other available currencies and the replacement of any such applicable benchmark by a replacement alternative benchmark rate or mechanism for loans made in the applicable currency. A facility fee on the total amount of the amended revolving credit facility is also payable quarterly, regardless of usage. The applicable margins for borrowings under the amended revolving credit facility and the facility fee percentage may change from time to time depending on changes in our consolidated leverage ratio.
Aptar has an unsecured money market borrowing arrangement to provide short-term financing of up to $30 million that is available in the U.S. No borrowing on this facility is permitted over a quarter end date. As such, no balance was utilized under this arrangement as of September 30, 2024 or December 31, 2023.
Long-Term Obligations
On February 26, 2024, we repaid in full the $100 million 3.49% Senior Unsecured Notes that were due in February 2024. On July 19, 2024, we repaid in full the €200 million 1.17% Senior Unsecured Notes that were due in July 2024. On September 5, 2024, we repaid in full the $50 million 3.4% Senior Unsecured Notes that were due in September 2024. These were repaid using borrowings from our revolving credit facility or the Term Loan.
15
Table of Contents
At September 30, 2024 and December 31, 2023, our long-term obligations consisted of the following:
September 30, 2024December 31, 2023
Notes payable 0.10% – 2.25%, due in monthly and annual installments through 2031
$16,893 $14,988 
Senior unsecured notes 3.4%, due in 2024
— 50,000 
Senior unsecured notes 3.5%, due in 2024
— 100,000 
Senior unsecured notes 1.2%, due in 2024
— 220,810 
Senior unsecured notes 3.6%, due in 2025
125,000 125,000 
Senior unsecured notes 3.6%, due in 2026
125,000 125,000 
Term loan 6.4% floating, due in 2027
166,000 — 
Senior unsecured notes 3.6%, due in 2032, net of discount of $0.8 million
399,232 399,154 
Finance Lease Liabilities24,917 26,478 
Unamortized debt issuance costs(4,016)(3,816)
$853,026 $1,057,614 
Current maturities of long-term obligations(30,295)(376,426)
Total long-term obligations$822,731 $681,188 
The aggregate long-term maturities, excluding finance lease liabilities and unamortized debt issuance costs, which are discussed in Note 7, due annually from the current balance sheet date for the next five years and thereafter are:
Year One$26,912 
Year Two134,438 
Year Three271,276 
Year Four111 
Year Five78 
Thereafter399,310 
Covenants
Our amended revolving credit facility and corporate long-term obligations require us to satisfy certain financial and other covenants including:
RequirementLevel at September 30, 2024
Consolidated Leverage Ratio (1) 
Maximum of 3.50 to 1.00
 
1.10 to 1.00
Consolidated Interest Coverage Ratio (1) 
Minimum of 3.00 to 1.00
 
16.81 to 1.00
________________________________________
(1)Definitions of ratios are included as part of the revolving credit facility agreement and the private placement agreements.
NOTE 7 – LEASES
We lease certain warehouse, plant and office facilities, as well as certain equipment, under non-cancelable operating and finance leases expiring at various dates through the year 2042. Most of the operating leases contain renewal options and certain leases include options to purchase the related asset during or at the end of the lease term.
Amortization expense related to finance leases is included in depreciation expense, while rent expense related to operating leases is included within cost of sales and selling, research & development and administrative expenses.
16
Table of Contents
The components of lease expense for the three and nine months ended September 30, 2024 and 2023 were as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Operating lease cost$4,795 $5,150 $14,530 $15,841 
Finance lease cost:
Amortization of right-of-use assets$1,715 $908 $4,976 $2,686 
Interest on lease liabilities299 289 897 883 
Total finance lease cost$2,014 $1,197 $5,873 $3,569 
Short-term lease and variable lease costs$5,255 $5,774 $15,451 $15,883 
Supplemental cash flow information related to leases were as follows:
Nine Months Ended September 30,20242023
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$14,845 $15,993 
Operating cash flows from finance leases976 883 
Financing cash flows from finance leases2,305 2,377 
Right-of-use assets obtained in exchange for lease obligations:
Operating leases$31,819 $7,764 
Finance leases1,347 401 
NOTE 8 – RETIREMENT AND DEFERRED COMPENSATION PLANS
We have various noncontributory retirement plans covering certain of our domestic and foreign employees. Benefits under our retirement plans are based on participants’ years of service and annual compensation as defined by each plan. Annual cash contributions to fund pension costs accrued under our domestic plans are generally at least equal to the minimum funding amounts required by the Employee Retirement Income Security Act of 1974, as amended (“ERISA”). Certain pension commitments under our foreign plans are also funded according to local requirements or at our discretion.
Effective January 1, 2021, our domestic noncontributory retirement plans were closed to new employees and employees who were rehired after December 31, 2020. These employees are instead eligible for additional contribution to their defined contribution 401(k) employee savings plan. All domestic employees with hire/rehire dates prior to January 1, 2021 are still eligible for the domestic pension plans and continue to accrue plan benefits after this date.
Components of Net Periodic Benefit Cost:
Domestic PlansForeign Plans
Three Months Ended September 30,2024202320242023
Service cost$2,366 $2,409 $1,605 $1,487 
Interest cost2,242 2,158 860 915 
Expected return on plan assets(3,116)(3,094)(549)(589)
Amortization of net loss— — 303 230 
Amortization of prior service cost— — 29 45 
Net periodic benefit cost$1,492 $1,473 $2,248 $2,088 
Curtailment— — (1,851)— 
Total Net periodic benefit cost$1,492 $1,473 $397 $2,088 
17
Table of Contents
Domestic PlansForeign Plans
Nine Months Ended September 30,2024202320242023
Service cost$7,097 $7,228 $4,838 $4,444 
Interest cost6,726 6,473 2,602 2,735 
Expected return on plan assets(9,347)(9,283)(1,671)(1,758)
Amortization of net loss— — 819 687 
Amortization of prior service cost— — 83 133 
Net periodic benefit cost$4,476 $4,418 $6,671 $6,241 
Curtailment— — (1,851)— 
Total Net periodic benefit cost$4,476 $4,418 $4,820 $6,241 
During the three months ended September 30, 2024, pension curtailment accounting was triggered as a result of restructuring in one of our entities in Europe. The remeasurement of the pension obligations resulted in a decrease of $1.9 million. The components of net periodic benefit cost, other than the service cost component, are included in the line miscellaneous income (expense), net in the Condensed Consolidated Statements of Income.
Employer Contributions
We currently have no minimum funding requirements for our domestic and foreign plans. There were no contributions to our domestic defined benefit plans during the nine months ended September 30, 2024 and we do not expect significant payments during the rest of 2024. We contributed $2.8 million to our foreign defined benefit plans during the nine months ended September 30, 2024 and do not expect additional significant contributions during the rest of 2024.
NOTE 9 – ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME
Changes in Accumulated Other Comprehensive (Loss) Income by Component:
Foreign CurrencyDefined Benefit Pension PlansDerivativesTotal
Balance - December 31, 2022$(328,740)$(5,951)$(6,675)$(341,366)
Other comprehensive (loss) income before reclassifications(28,294)63 (2,424)(30,655)
Amounts reclassified from accumulated other comprehensive income— 581 — 581 
Net current-period other comprehensive (loss) income(28,294)644 (2,424)(30,074)
Balance - September 30, 2023$(357,034)$(5,307)$(9,099)$(371,440)
Balance - December 31, 2023$(280,082)$(11,891)$(16,761)$(308,734)
Other comprehensive (loss) income before reclassifications(52)(532)(202)(786)
Amounts reclassified from accumulated other comprehensive income— 640 — 640 
Net current-period other comprehensive (loss) income(52)108 (202)(146)
Balance - September 30, 2024$(280,134)$(11,783)$(16,963)$(308,880)
18
Table of Contents
Reclassifications Out of Accumulated Other Comprehensive (Loss) Income:
Details about Accumulated Other
Comprehensive Income Components		Amount Reclassified from Accumulated Other Comprehensive IncomeAffected Line in the Statement
Where Net Income is Presented
Three Months Ended September 30,20242023
Defined Benefit Pension Plans
Amortization of net loss$303 $230 (1)
Amortization of prior service cost29 45 (1)
332 275 Total before tax
(96)(81)Tax impact
$236 $194 Net of tax
Total reclassifications for the period$236 $194 
Details about Accumulated Other
Comprehensive Income Components		Amount Reclassified from Accumulated Other Comprehensive IncomeAffected Line in the Statement
Where Net Income is Presented
Nine Months Ended September 30,20242023
Defined Benefit Pension Plans
Amortization of net loss$819 $687 (1)
Amortization of prior service cost83 133 (1)
902 820 Total before tax
(262)(239)Tax impact
$640 $581 Net of tax
Total reclassifications for the period$640 $581 
______________________________________________
(1)These accumulated other comprehensive income components are included in the computation of total net periodic benefit costs, net of tax. See Note 8 – Retirement and Deferred Compensation Plans for additional details.
NOTE 10 – DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES
We maintain a foreign exchange risk management policy designed to establish a framework to protect the value of our non-functional currency denominated transactions from adverse changes in exchange rates. Sales of our products can be denominated in a currency different from the currency in which the related costs to produce the product are denominated. Changes in exchange rates on such inter-country sales or intercompany loans can impact our results of operations. Our policy is not to engage in speculative foreign currency hedging activities, but to minimize our net foreign currency transaction exposure, defined as firm commitments and transactions recorded and denominated in currencies other than the functional currency. We may use foreign currency forward exchange contracts, options and cross currency swaps to economically hedge these risks.
For derivative instruments designated as hedges, we formally document the nature and relationships between the hedging instruments and the hedged items, as well as the risk management objectives, strategies for undertaking the various hedge transactions, and the method of assessing hedge effectiveness at inception. Quarterly thereafter, we formally assess whether the derivatives that are used in hedging transactions are highly effective in offsetting changes in the fair value or cash flows of the hedged item. Additionally, in order to designate any derivative instrument as a hedge of an anticipated transaction, the significant characteristics and expected terms of any anticipated transaction must be specifically identified, and it must be probable that the anticipated transaction will occur. All derivative financial instruments used as hedges are recorded at fair value in the Condensed Consolidated Balance Sheets (See Note 11 - Fair Value).
Cash Flow Hedge
For derivative instruments that are designated and qualify as cash flow hedges, the changes in fair values are recorded in accumulated other comprehensive loss and included in changes in derivative gain/loss. The changes in the fair values of derivatives designated as cash flow hedges are reclassified from accumulated other comprehensive loss to net income when the underlying hedged item is recognized in earnings. Cash flows from the settlement of derivative contracts designated as cash flow hedges offset cash flows from the underlying hedged items and are included in operating activities in the Condensed Consolidated Statements of Cash Flows.
19
Table of Contents
Net Investment Hedge
A significant number of our operations are located outside of the United States. Because of this, movements in exchange rates may have a significant impact on the translation of the financial condition and results of operations of our foreign subsidiaries. A weakening U.S. dollar has an additive effect on our financial condition and results of operations. Conversely, a strengthening U.S. dollar relative to foreign currencies has a dilutive translation effect. In some cases we maintain debt in these subsidiaries to offset the net asset exposure. In the event we plan on a full or partial liquidation of any of our foreign subsidiaries where our net investment is likely to be monetized, we will consider hedging the currency exposure associated with such a transaction.
On July 6, 2022, we entered into a seven-year USD/EUR fixed-to-fixed cross currency interest rate swap to effectively hedge the interest rate exposure relating to $203 million of the $400 million 3.60% Senior Unsecured Notes due March 2032, which were issued by AptarGroup, Inc. on March 7, 2022. This USD/EUR swap agreement exchanged $203 million of fixed-rate 3.60% USD debt to €200 million of fixed-rate 2.5224% euro debt. We pay semi-annual fixed rate interest payments on the euro notional amount of €2.5 million and receive semi-annual fixed rate interest payments on the USD notional amount of $3.7 million. This swap has been designated as a net investment hedge to effectively hedge the foreign exchange risk associated with €200 million of our euro denominated net assets. We elected the spot method for recording the net investment hedge. Gains and losses resulting from the settlement of the excluded components are recorded in interest expense in the Condensed Consolidated Statements of Income. Gains and losses resulting from the fair value adjustments to the cross currency swap agreements are recorded in accumulated other comprehensive (loss) income as the swaps are effective in hedging the designated risk. As of September 30, 2024, the fair value of the cross currency swap was a $22.5 million liability. The swap agreement will mature on September 15, 2029.
Other
As of September 30, 2024, we have recorded the fair value of foreign currency forward exchange contracts of $0.1 million in prepaid and other and $1.1 million in accounts payable, accrued and other liabilities on the Condensed Consolidated Balance Sheets. All forward exchange contracts outstanding as of September 30, 2024 had an aggregate notional contract amount of $77.2 million.
Fair Value of Derivative Instruments in the Condensed Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023
September 30, 2024December 31, 2023
Balance Sheet
Location
Derivatives Designated as Hedging InstrumentsDerivatives not Designated as Hedging InstrumentsDerivatives Designated as Hedging InstrumentsDerivatives not Designated as Hedging Instruments
Derivative Assets
Foreign Exchange ContractsPrepaid and other$— $145 $— $386 
$— $145 $— $386 
Derivative Liabilities
Foreign Exchange ContractsAccounts payable, accrued and other liabilities$— $1,052 $— $221 
Cross Currency Swap Contract (1)Accounts payable, accrued and other liabilities22,466 — 22,199 — 
$22,466 $1,052 $22,199 $221 
__________________________
(1)This cross currency swap agreement is composed of both an interest component and a foreign exchange component.
20
Table of Contents
The Effect of Derivatives Designated as Hedging Instruments on Accounting on Accumulated Other Comprehensive Income (Loss) for the Three Months Ended September 30, 2024 and 2023
Derivatives Designated as Hedging InstrumentsAmount of Gain (Loss)
Recognized in
Other Comprehensive
Income on Derivative		Location of (Loss)
Gain Recognized
in Income on
Derivatives		Amount of Gain (Loss)
Reclassified from
Accumulated
Other Comprehensive
Income on Derivative		Total Amount of Affected Income Statement Line Item
2024202320242023
Cross currency swap agreement:
Interest component$— $— Interest expense$— $— $(12,290)
Foreign exchange component(5,711)2,707 Miscellaneous, net— — 1,136 
$(5,711)$2,707 $— $— 
The Effect of Derivatives Designated as Hedging Instruments on Accumulated Other Comprehensive Income (Loss) for the Nine Months Ended September 30, 2024 and 2023
Derivatives Designated as Hedging InstrumentsAmount of Gain
Recognized in
Other Comprehensive
Income on Derivative		Location of Gain Recognized
in Income on
Derivatives		Amount of Gain
Reclassified from
Accumulated
Other Comprehensive
Income on Derivative		Total Amount of Affected Income Statement Line Item
2024202320242023
Cross currency swap agreement:
Interest component$— $— Interest expense$— $— $(32,526)
Foreign exchange component(202)(2,424)Miscellaneous, net— — (518)
$(202)$(2,424)$— $— 
The Effect of Derivatives Not Designated as Hedging Instruments on the Condensed Consolidated Statements of Income for the Three Months Ended September 30, 2024 and 2023
Derivatives Not Designated
as Hedging Instruments		Location of (Loss) Gain Recognized
in Income on Derivatives		Amount of (Loss) Gain
Recognized in Income
on Derivatives
20242023
Foreign Exchange ContractsOther (Expense) Income:
Miscellaneous, net		$(1,157)$44 
$(1,157)$44 
The Effect of Derivatives Not Designated as Hedging Instruments on the Condensed Consolidated Statements of Income for the Nine Months Ended September 30, 2024 and 2023
Derivatives Not Designated
as Hedging Instruments		Location of Loss Recognized
in Income on Derivatives		Amount of Loss
Recognized in Income
on Derivatives
20242023
Foreign Exchange ContractsOther (Expense) Income:
Miscellaneous, net		$(1,017)$(756)
$(1,017)$(756)
21
Table of Contents

Gross Amounts Offset in the Statement of Financial PositionNet Amounts Presented in the Statement of Financial PositionGross Amounts not Offset in the Statement of Financial Position
Gross AmountFinancial InstrumentsCash Collateral ReceivedNet Amount
September 30, 2024
Derivative Assets$145 — $145 — — $145 
Total Assets$145 — $145 — — $145 
Derivative Liabilities$23,518 — $23,518 — — $23,518 
Total Liabilities$23,518 — $23,518 — — $23,518 
December 31, 2023
Derivative Assets$386 — $386 — — $386 
Total Assets$386 — $386 — — $386 
Derivative Liabilities$22,420 — $22,420 — — $22,420 
Total Liabilities$22,420 — $22,420 — — $22,420 

NOTE 11 – FAIR VALUE
Authoritative guidelines require the categorization of assets and liabilities into three levels based upon the assumptions (inputs) used to price the assets or liabilities. Level 1 provides the most reliable measure of fair value, whereas Level 3 generally requires significant management judgment. The three levels are defined as follows:
•Level 1: Unadjusted quoted prices in active markets for identical assets and liabilities.
•Level 2: Observable inputs other than those included in Level 1. For example, quoted prices for similar assets or liabilities in active markets or quoted prices for identical assets or liabilities in inactive markets.
•Level 3: Unobservable inputs reflecting management’s own assumptions about the inputs used in pricing the asset or liability.
As of September 30, 2024, the fair values of our financial assets and liabilities were categorized as follows:
TotalLevel 1Level 2Level 3
Assets
Investment in equity securities (1)
$2,768 $2,768 $— $— 
Foreign exchange contracts (2)
145 — 145 — 
Convertible notes (3)
5,650 — — 5,650 
Total assets at fair value$8,563 $2,768 $145 $5,650 
Liabilities
Foreign exchange contracts (2)
$1,052 $— $1,052 $— 
Cross currency swap contract (2)
22,466 — 22,466 — 
Total liabilities at fair value$23,518 $— $23,518 $— 
22
Table of Contents
As of December 31, 2023, the fair values of our financial assets and liabilities were categorized as follows:
TotalLevel 1Level 2Level 3
Assets
Investment in equity securities (1)
$1,106 $1,106 $— $— 
Foreign exchange contracts (2)
386 — 386 — 
Convertible note (3)
5,650 — — 5,650 
Total assets at fair value$7,142 $1,106 $386 $5,650 
Liabilities
Foreign exchange contracts (2)
$221 $— $221 $— 
Cross currency swap contract (2)
22,199 — 22,199 — 
Total liabilities at fair value$22,420 $— $22,420 $— 
________________________________________________
(1)Investment in PureCycle Technologies (“PCT” or “PureCycle”). See Note 18 – Investment in Equity Securities for discussion of this investment.
(2)Market approach valuation technique based on observable market transactions of spot and forward rates.
(3)Investment in convertible notes in Enable Injections, Inc. and Siklus Refill Pte, Ltd. The investments are included within Miscellaneous assets in our Condensed Consolidated Balance Sheets.
The carrying amounts of our other current financial instruments such as cash and equivalents, accounts and notes receivable, notes payable and current maturities of long-term obligations approximate fair value due to the short-term maturity of the instrument. We consider our long-term debt obligations a Level 2 liability and utilize the market approach valuation technique based on interest rates that are currently available to us for issuance of debt with similar terms and maturities. The estimated fair value of our long-term obligations was $775.5 million as of September 30, 2024 and $620.7 million as of December 31, 2023.
NOTE 12 – COMMITMENTS AND CONTINGENCIES
In the normal course of business, we are subject to a number of lawsuits and claims both actual and potential in nature. While management believes the resolution of these claims and lawsuits will not have a material adverse effect on our financial position, results of operations or cash flows, claims and legal proceedings are subject to inherent uncertainties, and unfavorable outcomes could occur that could include amounts in excess of any accruals which management has established. Were such unfavorable final outcomes to occur, it is possible that they could have a material adverse effect on our financial position, results of operations and cash flows.
Under our Certificate of Incorporation, we have agreed to indemnify our officers and directors for certain events or occurrences while the officer or director is, or was, serving at our request in such capacity. The maximum potential amount of future payments we could be required to make under these indemnification agreements is unlimited; however, we have a directors and officers liability insurance policy that covers a portion of our exposure. As a result of our insurance policy coverage, we believe the estimated fair value of these indemnification agreements is minimal. We have no liabilities recorded for these agreements as of September 30, 2024 and December 31, 2023.
We are periodically subject to loss contingencies resulting from custom duties assessments. We accrue for anticipated costs when an assessment has indicated that a loss is probable and can be reasonably estimated. We have received claims worth approximately $12 million in principal and $14 million to $15 million for interest and penalties. We are currently defending our position with respect to these claims in the respected administrative procedures. Due to uncertainty in the amount of the assessment and the timing of our appeal, no liability is recorded as of September 30, 2024.
We will continue to evaluate these liabilities periodically based on available information, including the progress of remedial investigations, the status of discussions with regulatory authorities regarding the methods and extent of remediation and the apportionment of costs and penalties among potentially responsible parties.
NOTE 13 – STOCK REPURCHASE PROGRAM
On April 18, 2019, we announced a share repurchase authorization of up to $350 million of common stock. We may repurchase shares through the open market, privately negotiated transactions or other programs, subject to market conditions. On October 10, 2024, we announced a share repurchase authorization of up to $500 million of common stock. This authorization replaces previous authorizations and has no expiration date.
During the three and nine months ended September 30, 2024, we repurchased approximately 95 thousand shares for $14.2 million and 215 thousand shares for $31.3 million, respectively. During the three and nine months ended September 30, 2023, we repurchased approximately 66 thousand shares for $8.3 million and 318 thousand shares for $37.3 million, respectively.
23
Table of Contents
NOTE 14 – STOCK-BASED COMPENSATION
We issue restricted stock units (“RSUs”), which consist of time-based and performance-based awards, to employees under stock awards plans approved by stockholders. In addition, RSUs are issued to non-employee directors under a Restricted Stock Unit Award Agreement for Directors pursuant to the Company’s 2018 Equity Incentive Plan. RSUs granted to employees vest according to a specified performance period and/or vesting period. Time-based RSUs generally vest over three years. Performance-based RSUs vest at the end of the specified performance period, generally three years, assuming required performance or market vesting conditions are met.
For awards granted in the first quarter of 2023 and thereafter, our performance-based RSUs will vest solely based on our return on invested capital (“ROIC”). Award share payouts depend on the extent to which the ROIC performance goal has been achieved, but the final payout is adjusted by a total shareholder return (“TSR”) modifier.
At the time of vesting, the vested shares of common stock are issued in the employee’s name. In addition, RSU awards are generally net settled (shares are withheld to cover the employee tax obligation). RSUs granted to directors are only time-based and generally vest on or around the first anniversary of the date of grant.
The fair value of both time-based RSUs and performance-based RSUs pertaining to internal performance metrics is determined using the closing price of our common stock on the grant date. The fair value of performance-based RSUs pertaining to TSR is estimated using a Monte Carlo simulation. Inputs and assumptions used to calculate the fair value are shown in the table below. The fair value of these RSUs is expensed over the vesting period using the straight-line method or using the graded vesting method when an employee becomes eligible to retain the award at retirement.
Nine Months Ended September 30,20242023
Fair value per stock award$145.79 $116.17 
Grant date stock price$141.00 $111.38 
Assumptions:
Aptar's stock price expected volatility18.80 %20.00 %
Expected average volatility of peer companies34.80 %39.70 %
Correlation assumption30.70 %33.30 %
Risk-free interest rate4.51 %3.83 %
Dividend yield assumption1.16 %1.36 %
A summary of RSU activity as of September 30, 2024 and changes during the nine month period then ended is presented below:
Time-Based RSUsPerformance-Based RSUs
UnitsWeighted Average
Grant-Date Fair Value		UnitsWeighted Average
Grant-Date Fair Value
Nonvested at January 1, 2024335,874 $115.15 514,383 $130.10 
Granted125,454 137.03 129,614 145.79 
Vested(176,820)119.33 (97,764)162.33 
Forfeited(4,087)118.06 (32,007)143.88 
Nonvested at September 30, 2024280,421 $122.18 514,226 $127.11 
Included in the time-based RSU activity for the nine months ended September 30, 2024 are 10,208 units granted to non-employee directors and 11,508 units vested related to non-employee directors.
Nine Months Ended September 30,20242023
Compensation expense$31,677 $32,209 
Fair value of units vested35,434 27,662 
Intrinsic value of units vested38,578 32,319 
The actual tax benefit realized for the tax deduction from RSUs was approximately $7.2 million and $5.6 million in the nine months ended September 30, 2024 and 2023, respectively. As of September 30, 2024, there was $51.2 million of total unrecognized compensation cost relating to RSU awards which is expected to be recognized over a weighted-average period of 1.8 years.
24
Table of Contents
Historically we issued stock options to our employees and non-employee directors. We did not issue stock options between 2019 and 2022. Stock options were reinstituted in 2023 and valued based on the Black-Scholes model and generally vest ratably over three years and expire 10 years after grant.
The Company uses historical data to estimate expected life and volatility. The weighted-average fair value of stock options granted under the stock awards plans were $36.07 per share for all employees during the first nine months of 2024. The weighted-average fair value of stock options granted under the stock awards plans were $19.84 and $24.23 per share for executive officers and all other employees, respectively, during the first nine months of 2023. Aptar executive officers received stock options with an exercise price that was 110% of the closing market price on the date of grant. These values were estimated on the respective dates of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions:
Stock Award Plans:
Nine Months Ended September 30,20242023
Dividend Yield1.28 %1.41 %
Expected Stock Price Volatility17.03 %16.55 %
Risk-free Interest Rate4.51 %3.57 %
Expected Life of Option (years)7.07.0
 A summary of option activity under our stock plans during the nine months ended September 30, 2024 is presented below:
Stock Awards PlansDirector Stock Option Plans
OptionsWeighted Average
Exercise Price		OptionsWeighted Average
Exercise Price
Outstanding, January 1, 20242,182,784 $80.63 19,000 $66.59 
Granted249,805 141.00 — — 
Exercised(610,124)70.98 (19,000)66.59 
Forfeited or expired(9,666)107.82 — — 
Outstanding at September 30, 20241,812,799 $92.05 — $— 
Exercisable at September 30, 20241,361,396 $79.52 — $— 
Weighted-Average Remaining Contractual Term (Years):
Outstanding at September 30, 20244.30.0
Exercisable at September 30, 20242.70.0
Aggregate Intrinsic Value:
Outstanding at September 30, 2024$123,515 $— 
Exercisable at September 30, 2024$109,830 $— 
Intrinsic Value of Options Exercised During the Nine Months Ended:
September 30, 2024$43,779 $1,394 
September 30, 2023$27,392 $1,978 
Nine Months Ended September 30,20242023
Compensation expense (included in SG&A)$5,678 $3,561 
Compensation expense (included in Cost of sales)607 314 
Compensation expense, Total$6,285 $3,875 
Compensation expense, net of tax6,121 3,875 
Grant date fair value of options vested2,306 — 
The increase in stock option expense is due to the newly issued options as discussed above. Cash received from option exercises for the nine months ended September 30, 2024 and 2023 was approximately $44.4 million and $39.7 million, respectively. The actual tax benefit realized for the tax deduction from option exercises was approximately $10.3 million and $6.8 million in the nine months ended September 30, 2024 and 2023, respectively. As of September 30, 2024, there was $5.2 million of total unrecognized compensation cost relating to stock option awards which is expected to be recognized over a weighted-average period of 2.1 years.
25
Table of Contents
NOTE 15 – EARNINGS PER SHARE
Basic net income per share is calculated by dividing net income attributable to Aptar by the weighted-average number of common shares outstanding during the period. Diluted net income per share is calculated by dividing the net income attributable to Aptar by the weighted-average number of common and common equivalent shares outstanding during the applicable period. The difference between basic and diluted earnings per share is attributable to stock-based compensation awards. Stock-based compensation awards for which total employee proceeds exceed the average market price over the applicable period would have an antidilutive effect on earnings per share, and accordingly, are excluded from the calculation of diluted earnings per share. The reconciliation of basic and diluted earnings per share for the three and nine months ended September 30, 2024 and 2023 were as follows:
Three Months Ended
September 30, 2024September 30, 2023
DilutedBasicDilutedBasic
Consolidated operations
Income available to common stockholders$100,039 $100,039 $84,296 $84,296 
Average equivalent shares
Shares of common stock66,445 66,445 65,707 65,707 
Effect of dilutive stock-based compensation
Stock options737 — 874 — 
Restricted stock534 — 454 — 
Total average equivalent shares67,716 66,445 67,035 65,707 
Net income per share$1.48 $1.51 $1.26 $1.28 
Nine Months Ended
September 30, 2024September 30, 2023
DilutedBasicDilutedBasic
Consolidated operations
Income available to common stockholders$273,597 $273,597 $222,132 $222,132 
Average equivalent shares
Shares of common stock66,274 66,274 65,550 65,550 
Effect of dilutive stock-based compensation
Stock options768 —886 —
Restricted stock532 —429 —
Total average equivalent shares67,574 66,274 66,865 65,550 
Net income per share$4.05 $4.13 $3.32 $3.39 
NOTE 16 – SEGMENT INFORMATION
We are organized into three reporting segments. Operations that sell proprietary dispensing systems, drug delivery systems, sealing solutions and services to the prescription drug, consumer health care, injectables, active material science solutions and digital health markets form our Aptar Pharma segment. Operations that sell dispensing systems and sealing solutions to the beauty, personal care and home care markets form our Aptar Beauty segment. Operations that sell dispensing closures, sealing solutions and food service trays to the food, beverage, personal care, home care, beauty and healthcare markets form our Aptar Closures segment. Aptar Pharma and Aptar Beauty are named for the markets they serve with multiple product platforms, while Aptar Closures is named primarily for a single product platform that serves all available markets.
The accounting policies of the segments are the same as those described in Part II, Item 8, Note 1 - Summary of Significant Accounting Policies in our Annual Report on Form 10-K for the year ended December 31, 2023. We evaluate performance of our reporting segments and allocate resources based upon Adjusted EBITDA. Adjusted EBITDA is defined as earnings before net interest, taxes, depreciation, amortization, restructuring initiatives, acquisition-related costs, net unrealized investment gains and losses related to observable market price changes on equity securities and other special items.
26
Table of Contents
Financial information regarding our reporting segments is shown below:
Three Months Ended
September 30,		Nine Months Ended
September 30,
2024202320242023
Total Sales:
Aptar Pharma$420,753 $389,423 $1,243,026 $1,136,544 
Aptar Beauty308,955 330,467 972,535 1,002,209 
Aptar Closures187,324 181,562 547,002 539,472 
Total Sales$917,032 $901,452 $2,762,563 $2,678,225 
Less: Intersegment Sales:
Aptar Pharma$159 $235 $606 $610 
Aptar Beauty6,096 6,487 20,869 22,253 
Aptar Closures1,486 1,733 6,286 6,392 
Total Intersegment Sales$7,741 $8,455 $27,761 $29,255 
Net Sales:
Aptar Pharma$420,594 $389,188 $1,242,420 $1,135,934 
Aptar Beauty302,859 323,980 951,666 979,956 
Aptar Closures185,838 179,829 540,716 533,080 
Net Sales$909,291 $892,997 $2,734,802 $2,648,970 
Adjusted EBITDA (1):
Aptar Pharma$151,594 $136,344 $425,260 $371,508 
Aptar Beauty40,221 41,070 125,993 121,375 
Aptar Closures31,980 27,607 86,259 81,387 
Corporate & Other, unallocated(15,411)(11,659)(57,528)(45,996)
Acquisition-related costs (2)— — (140)(255)
Restructuring Initiatives (3)(3,864)(6,161)(9,659)(19,628)
Curtailment gain related to restructuring initiatives (5)
1,851 — 1,851 — 
Net unrealized investment (loss) gain (4)1,043 (5,428)1,495 (2,349)
Depreciation and amortization(67,015)(62,686)(196,332)(184,212)
Interest Expense(12,290)(9,984)(32,526)(29,900)
Interest Income3,022 946 9,022 2,266 
Income before Income Taxes$131,131 $110,049 $353,695 $294,196 
________________________________________________
(1)We evaluate performance of our reporting segments and allocate resources based upon Adjusted EBITDA. Adjusted EBITDA is defined as earnings before net interest, taxes, depreciation, amortization, restructuring initiatives, acquisition-related costs, net unrealized investment gains and losses related to observable market price changes on equity securities and other special items.
(2)Acquisition-related costs include transaction costs (and purchase accounting adjustments related to acquisitions and investments) (see Note 17 - Acquisitions and Note 18 – Investments in Equity Securities for further details).
27
Table of Contents
(3)Restructuring Initiatives includes expense items for the three and nine months ended September 30, 2024 and 2023 as follows (see Note 19 – Restructuring Initiatives for further details):
Three Months Ended
September 30,		Nine Months Ended
September 30,
2024202320242023
Restructuring Initiatives by Plan:
Optimization initiative$3,864 $6,586 $9,676 $20,069 
Prior year initiatives— (425)(17)(441)
Total Restructuring Initiatives$3,864 $6,161 $9,659 $19,628 
Restructuring Initiatives by Segment:
Aptar Pharma$564 $92 $653 $1,657 
Aptar Beauty1,962 2,880 5,871 12,650 
Aptar Closures877 3,098 2,530 4,060 
Corporate & Other461 91 605 1,261 
Total Restructuring Initiatives$3,864 $6,161 $9,659 $19,628 
(4)Net unrealized investment (loss) gain represents the change in fair value of our investment in PCT (see Note 18 – Investment in Equity Securities for further details).
(5)The curtailment gain is included in the line miscellaneous income (expense), net in the Condensed Consolidated Statements of Income (see Note 8 - Retirement and Deferred Compensation Plans).
NOTE 17 – ACQUISITIONS
Business Combinations
On August 1, 2023, we paid the remaining $5.2 million purchase price in relation to the 2021 Hengyu acquisition. No further liability remains outstanding for this acquisition.
On March 1, 2023, we completed the acquisition of all the outstanding capital stock of iD SCENT. Located in Lyon, France, iD SCENT is an expert producer of paper fragrance sampling solutions that present multiple sustainability features. The purchase price was approximately $9.4 million (net of $1.4 million cash acquired) and was funded with cash on hand. The results of iD SCENT have been included in the consolidated financial statements within our Aptar Beauty segment since the date of acquisition.
Also on March 1, 2023, we completed the acquisition of 80% of the equity interest of Gulf Closures W.L.L. (“Gulf Closures”). Gulf Closures, located in Bahrain, is a closure manufacturer for beverage products. The purchase price for 80% ownership was approximately $1.5 million (net of $1.2 million cash acquired) and was funded with cash on hand. This values the full company equity at approximately $3.3 million and implies a non-controlling interest valued at approximately $0.7 million as of the acquisition date. The results of Gulf Closures have been included in the consolidated financial statements within our Aptar Closures segment since the date of acquisition.
28
Table of Contents
NOTE 18 – INVESTMENT IN EQUITY SECURITIES
Our investment in equity securities consisted of the following:
September 30,
2024		December 31,
2023
Equity Method Investments:
BTY$33,069 $33,090 
Sonmol4,796 4,751 
Desotec GmbH1,000 905 
Other Investments:
PureCycle2,768 1,106 
YAT5,414 5,352 
Loop2,894 2,894 
Others1,111 1,105 
$51,052 $49,203 
Equity Method Investments
Goldrain
On October 22, 2024, we acquired 40% of the equity interests in Ningbo Jinyu Technology Industry Co., Ltd., doing business as Goldrain, (referred to as “Goldrain”), a leading manufacturer of dispensing technologies in China for an approximate purchase price of $99 million. Goldrain is a leading manufacturer specialized in developing and producing packages for skin care, cosmetic, household, cleaning, personal care and perfumery products.
BTY
On January 1, 2020, we acquired 49% of the equity interests in three related companies: Suzhou Hsing Kwang, Suqian Hsing Kwang and Suzhou BTY (collectively referred to as “BTY”) for an approximate purchase price of $32.0 million. We have a call option to acquire an additional 26% to 31% of BTY’s equity interests following the initial lock-up period of 5 years based on a predetermined formula. Subsequent to the second lock-up period, which ends 3 years after the initial lock-up period, we have a call option to acquire the remaining equity interests of BTY based on a predetermined formula. Additionally, the selling shareholders of BTY have a put option for the remaining equity interest to be acquired by Aptar based on a predetermined formula. The BTY entities are leading Chinese manufacturers of high quality, decorative metal components, metal-plastic sub-assemblies, and complete color cosmetics packaging solutions for the beauty industry. For the nine months ended September 30, 2024 and September 30, 2023, Aptar had purchases of $8.7 million and $10.7 million, respectively, from BTY. As of September 30, 2024 and December 31, 2023, approximately $2.0 million and $1.8 million, respectively, was due to BTY and included in accounts payable, accrued and other liabilities on our Condensed Consolidated Balance Sheets.
Sonmol
On April 1, 2020, we invested $5.0 million to acquire 30% of the equity interests in Healthcare, Inc., Shanghai Sonmol Internet Technology Co., Ltd. and its subsidiary, Shanghai Sonmol Medical Equipment Co., Ltd. (collectively referred to as “Sonmol”). Sonmol is a leading Chinese pharmaceutical company that provides consumer electric devices and connected devices for asthma control.
Desotec GmbH
During 2009, we invested €574 thousand to acquire 23% of the equity interests in Desotec GmbH, a leading manufacturer of specialty assembly machines for bulk processing for the pharmaceutical, beauty and closures markets.
Other Investments
In prior years, we invested, through a series of transactions, an aggregate amount of $2.9 million in preferred equity investments in Loop, a sustainability company.
29
Table of Contents
In prior years, we also invested, through a series of transactions, $3.0 million in PureCycle and received $0.7 million of equity in exchange for our resource dedication for technological partnership and support. In March 2021, PureCycle became a publicly-traded company and listed its common stock on Nasdaq under the ticker symbol “PCT,” At that time, our investment in PureCycle was converted into shares of common stock of PCT resulting in less than a 1% ownership interest. This investment is now recorded at fair value based on observable market prices for identical assets and the change in fair value is recorded as a net investment gain or loss in the Condensed Consolidated Statements of Income.
We have sold the following PCT shares related to the PureCycle investment:
Shares SoldProceedsRealized Gain
2021191,349$2,434 $2,000 
2022157,600$1,599 $1,213 
2023
510,449$5,604 $4,188 
.........................................................................On April 26, 2024, we received $0.2 million of equity in exchange for our resource dedication for technological partnership and support. For the three and nine months ended September 30, 2024 and 2023, we recorded the following net investment gain or loss on our investment in PureCycle:
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Net investment gain (loss)
$1,043 $(1,240)$1,495 $1,839 
On July 7, 2021, we invested approximately $5.9 million to acquire 10% of the equity interests in YAT, a multi-functional, science-driven online skincare solutions company.
There were no indications of impairment noted in the nine months ended September 30, 2024 and 2023 related to these investments.
NOTE 19 – RESTRUCTURING INITIATIVES
As part of our ongoing efforts to better leverage our fixed cost base through growth and cost reduction measures, during the three and nine months ended September 30, 2024, we recognized $3.9 million and $9.7 million of restructuring costs related to this initiative, respectively. For the three and nine months ended September 30, 2023, we recognized $6.6 million and $20.1 million of restructuring costs related to this initiative, respectively. The cumulative expense incurred as of September 30, 2024 was $61.3 million.
As of September 30, 2024, we have recorded the following activity associated with our optimization initiative:
Beginning Reserve at December 31, 2023
Net Charges for the Nine Months Ended September 30, 2024
Cash PaidInterest and
FX Impact		Ending Reserve at September 30, 2024
Employee severance$27,078 $6,003 $(15,321)$38 $17,798 
Professional fees and other costs2,810 3,673 (3,560)36 2,959 
Totals$29,888 $9,676 $(18,881)$74 $20,757 
During the three months ended September 30, 2024, pension curtailment accounting was triggered as a result of restructuring in one of our entities in Europe. The remeasurement of the pension obligations resulted in a decrease of $1.9 million. The curtailment gain is included in the line miscellaneous income (expense), net in the Condensed Consolidated Statements of Income.

30
Table of Contents
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
(AMOUNTS IN THOUSANDS, EXCEPT PER SHARE AMOUNTS, OR AS OTHERWISE INDICATED)
RESULTS OF OPERATIONS
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Net sales100.0 %100.0 %100.0 %100.0 %
Cost of sales (exclusive of depreciation and amortization shown below)61.4 63.5 62.5 64.1 
Selling, research & development and administrative15.6 15.5 16.2 16.1 
Depreciation and amortization7.4 7.0 7.2 7.0 
Restructuring initiatives0.4 0.7 0.3 0.7 
Operating income15.2 13.3 13.8 12.1 
Interest expense(1.4)(1.1)(1.2)(1.1)
Other expense0.6 0.1 0.3 0.1 
Income before income taxes14.4 12.3 12.9 11.1 
Net Income11.0 9.4 10.0 8.4 
Effective tax rate23.8 %23.4 %22.7 %24.6 %
Adjusted EBITDA margin (1)22.9 %21.7 %21.2 %19.9 %
________________________________________________
(1)Adjusted EBITDA margin is calculated as Adjusted EBITDA divided by Reported Net Sales. See the reconciliation under “Non-U.S. GAAP Measures.”
NET SALES
We reported net sales of $909.3 million for the quarter ended September 30, 2024, which represents a 2% increase compared to $893.0 million reported during the third quarter of 2023. The U.S. dollar weakened against most European currencies but strengthened against most Latin American currencies, resulting in no significant currency translation impact at the consolidated level. Therefore, core sales, which excludes acquisitions and changes in foreign currency rates, also increased by 2% in the third quarter of 2024 compared to the same period in 2023. Our 2% core sales increase was due to strong volume growth in our prescription, food, active material and personal care applications, which more than compensated for lower volumes in our prestige fragrance applications and lower tooling sales.
Third Quarter 2024
Net Sales Change over Prior Year		Aptar
Pharma		Aptar
Beauty		Aptar
Closures		Total
Reported Net Sales Growth8 %(7)%3 %2 %
Currency Effects (1)(1)%1 %1 %— %
Core Sales Growth7 %(6)%4 %2 %
Reported net sales for the first nine months of 2024 increased 3% to $2.73 billion compared to $2.65 billion for the first nine months of 2023. Changes in foreign currency exchange rates and our acquisitions of iD SCENT and Gulf Closures did not have a significant impact on our consolidated results during the first nine months of 2024. Therefore, core sales, which exclude acquisitions and changes in foreign currency rates, increased by 3% in the first nine months of 2024 compared to the same period in 2023. Our 3% core sales was again due to strong volume growth for products in our prescription and food applications along with increases in injectable and active material applications, which more than compensated lower tooling sales and pricing adjustments.
31
Table of Contents
Nine Months Ended September 30, 2024
Net Sales Change over Prior Year		Aptar
Pharma		Aptar
Beauty		Aptar
Closures		Total
Reported Net Sales Growth9 %(3)%1 %3 %
Currency Effects (1)— %— %1 %— %
Acquisitions— %— %— %— %
Core Sales Growth9 %(3)%2 %3 %
________________________________________________
(1)Currency effects are calculated by translating last year’s amounts at this year’s foreign exchange rates.
The following table sets forth, for the periods indicated, net sales by geographic location based on shipped to locations:
Three Months Ended September 30,Nine Months Ended September 30,
2024% of Total2023% of Total2024% of Total2023% of Total
Domestic$291,571 32 %$267,016 30 %$859,294 31 %$778,037 29 %
Europe445,129 49 %455,181 51 %1,369,648 50 %1,392,626 53 %
Latin America69,155 8 %77,909 9 %219,028 8 %219,086 8 %
Asia103,436 11 %92,891 10 %286,832 11 %259,221 10 %
For further discussion on net sales by reporting segment, please refer to the analysis of segment net sales and segment Adjusted EBITDA on the following pages.
COST OF SALES (EXCLUSIVE OF DEPRECIATION AND AMORTIZATION SHOWN BELOW)
Cost of sales (“COS”) as a percent of net sales decreased to 61.4% in the third quarter of 2024 compared to 63.5% in the third quarter of 2023. Our COS percentage was positively impacted by an improved mix of our higher-margin Pharma services and product sales compared to the same period in 2023. We also benefited from improved operational performance and cost management initiatives, which offset an increase in input costs.
For the first nine months of 2024, COS as a percent of net sales decreased to 62.5% compared to 64.1% in the same period in 2023. This decrease is mainly due to an improved mix of our higher value Pharma services and product sales along with improved operational performance and cost management initiatives as discussed above. During the prior year period, we also incurred approximately $16 million of incremental costs related to our injectables Enterprise Resource Planning (“ERP”) system implementation which did not repeat during 2024.
SELLING, RESEARCH & DEVELOPMENT AND ADMINISTRATIVE
Selling, research & development and administrative expenses (“SG&A”) increased by approximately $3.5 million to $141.6 million in the third quarter of 2024 compared to $138.1 million during the same period in 2023. Excluding changes in foreign currency rates, SG&A increased by approximately $3.3 million in the quarter. Improvements from our cost management initiatives were more than offset by higher compensation costs, including accruals related to our current short-term incentive compensation and certain equity compensation programs. SG&A as a percentage of net sales increased slightly to 15.6% in the third quarter of 2024 compared to 15.5% in the same period in 2023.
Our selling, research & development and administrative expenses (“SG&A”) increased by $16.2 million to $443.7 million in the first nine months of 2024 compared to $427.5 million during the same period in 2023. Excluding changes in foreign currency rates, SG&A increased by approximately $16.4 million in the first nine months of 2024 compared to the first nine months of 2023. Incremental costs related to our acquisitions of iD SCENT and Gulf Closures were $0.4 million. As discussed above, improvements from our cost management initiatives for the first nine months of 2024 were more than offset by higher compensation costs mentioned above. We also incurred approximately $3.4 million of costs to evaluate potential acquisition targets during the second quarter of 2024. SG&A as a percentage of net sales increased to 16.2% in the first nine months of 2024 compared to 16.1% in the same period in 2023.
DEPRECIATION AND AMORTIZATION
Reported depreciation and amortization expenses increased by approximately $4.3 million to $67.0 million in the third quarter of 2024 compared to $62.7 million during the same period in 2023. Changes in foreign currency rates did not significantly affect depreciation and amortization during the third quarter 2024 compared to the third quarter of 2023. The majority of this increase relates to higher capital spending during the prior years to support our growth strategy, including new manufacturing facilities commencing production during the last year. Depreciation and amortization as a percentage of net sales increased to 7.4% in the third quarter of 2024 compared to 7.0% in the same period of the prior year.
32
Table of Contents
Depreciation and amortization expenses increased by approximately $12.1 million to $196.3 million in the first nine months of 2024 compared to $184.2 million during the same period a year ago. Excluding changes in foreign currency rates, depreciation and amortization increased by approximately $12.2 million in the first nine months of 2024 compared to the same period a year ago. Incremental depreciation and amortization costs related to our acquisitions of iD SCENT and Gulf Closures were $0.3 million. As discussed above, this increase is due to higher internal capital investments made during the prior years. Depreciation and amortization as a percentage of net sales increased to 7.2% in the first nine months of 2024 compared to 7.0% in the same period of the prior year.
RESTRUCTURING INITIATIVES
As part of our ongoing efforts to better leverage our fixed cost base through growth and cost reduction measures, during the three and nine months ended September 30, 2024, we recognized $3.9 million and $9.7 million of operational restructuring costs related to this initiative, respectively. For the three and nine months ended September 30, 2023, we recognized $6.6 million and $20.1 million of restructuring costs related to this initiative, respectively. The cumulative expense incurred as of September 30, 2024 was $61.3 million.
Restructuring costs for the three and nine months ended September 30, 2024 and 2023 were as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
2024202320242023
Restructuring Initiatives by Plan:
Optimization initiative$3,864 $6,586 $9,676 $20,069 
Prior year initiatives— (425)(17)(441)
Total Restructuring Initiatives$3,864 $6,161 $9,659 $19,628 
Restructuring Initiatives by Segment:
Aptar Pharma$564 $92 $653 $1,657 
Aptar Beauty1,962 2,880 5,871 12,650 
Aptar Closures877 3,098 2,530 4,060 
Corporate & Other461 91 605 1,261 
Total Restructuring Initiatives$3,864 $6,161 $9,659 $19,628 
During the three months ended September 30, 2024, pension curtailment accounting was triggered as a result of restructuring in one of our entities in Europe. The remeasurement of the pension obligations resulted in a decrease of $1.9 million. The curtailment gain is included in the line miscellaneous income (expense), net in the Condensed Consolidated Statements of Income.
OPERATING INCOME
Operating income increased approximately $19.0 million to $138.3 million in the third quarter of 2024 compared to $119.3 million in the same period a year ago. Excluding changes in foreign currency rates, operating income increased by approximately $17.7 million in the quarter compared to the same period a year ago mainly due to the strong sales growth in our Pharma segment along with improved operational performance and cost management initiatives. Operating income as a percentage of net sales increased to 15.2% in the third quarter of 2024 compared to 13.3% in the prior year period.
For the first nine months of 2024, operating income increased approximately $56.6 million to $376.4 million compared to $319.8 million in the same period of the prior year. Excluding changes in foreign currency rates, operating income increased by approximately $55.1 million in the first nine months of 2024 compared to the same period a year ago as income from our strong Pharma segment growth and improved operational performance and cost management initiatives drove the increase. Operating income as a percentage of net sales increased to 13.8% in the first nine months of 2024 compared to 12.1% for the same period in the prior year.
INTEREST EXPENSE
Interest expense increased approximately $2.3 million to $12.3 million in the third quarter of 2024 compared to $10.0 million for the same period of the prior year. During 2024, we repaid more than $370 million of private placement debt having interest rates between 1.2% and 3.5% and initiated term loan and revolving credit facility borrowings having current interest rates between 4.5% and 6.0%.
Interest expense increased $2.6 million to $32.5 million in the first nine months of 2024 compared to the same period in 2023. As discussed above, this increase is mainly related to higher rates on our current term loan and revolving credit facility borrowings. See Note 6 - Debt to the Condensed Consolidated Financial Statements for further details.
33
Table of Contents
NET OTHER INCOME (EXPENSE)
Net other income increased $4.4 million to $5.1 million of income in the third quarter of 2024 from $0.7 million of income in the same period of the prior year. Interest income increased by $2.1 million due to increased cash flow generated from operations and therefore higher interest earned on higher cash deposits over the past year. We also recorded an increase in the value of our PureCycle investment of $2.3 million over the prior year period. This investment is recorded at fair value based on observable market prices for identical assets with the change in fair value being recorded as a net investment gain or loss in the Condensed Consolidated Statements of Income. During the third quarter of 2024, we also reported a $1.9 million gain on pension curtailment for a facility closure in France, which more than compensated for lower contributions from our equity results from affiliates.
Net other income increased $5.6 million to $9.8 million of income for the nine months ended September 30, 2024 from $4.3 million of income in the same period of the prior year. Interest income increased by approximately $6.8 million. This increase, along with the pension curtailment gain discussed above, more than compensated for the lower contributions from our equity results from affiliates and the change in the fair value of our PureCycle investment which resulted in $0.3 million less income during the first nine months of 2024 compared to the prior year period.
PROVISION FOR INCOME TAXES
The tax provision for interim periods is determined using the estimated annual effective consolidated tax rate, based on the current estimate of full-year earnings and related estimated full year-taxes, adjusted for the impact of discrete quarterly items.
The effective tax rate for the three months ended September 30, 2024 and 2023, respectively, was 23.8% and 23.4%. The effective tax rate for the three months ended September 30, 2024 was slightly higher than the same period of 2023 primarily due to an unfavorable mix of earnings forecasted in the second half of 2024
The effective tax rate for the nine months ended September 30, 2024 and 2023, respectively, was 22.7% and 24.6%. On a nine-month basis, the effective tax rate was lower than the same period of 2023 primarily due to increased tax benefits from share-based compensation and tax incentives in certain non-U.S. jurisdictions for intellectual property development activities.
NET INCOME ATTRIBUTABLE TO APTARGROUP, INC.
We reported net income attributable to AptarGroup, Inc. of $100.0 million and $273.6 million in the three and nine months ended September 30, 2024, respectively, compared to $84.3 million and $222.1 million for the same periods in the prior year.
APTAR PHARMA SEGMENT
Operations that sell proprietary dispensing systems, drug delivery systems, sealing solutions and services to the prescription drug, consumer health care, injectables, active material science solutions and digital health markets form our Aptar Pharma segment.
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Net Sales$420,594 $389,188 $1,242,420 $1,135,934 
Adjusted EBITDA (1)151,594 136,344 425,260 371,508 
Adjusted EBITDA margin (1)36.0 %35.0 %34.2 %32.7 %
________________________________________________
(1)Adjusted EBITDA is calculated as earnings before net interest, taxes, depreciation, amortization, restructuring initiatives, acquisition-related costs, net unrealized investment gains and losses related to observable market price changes on equity securities and other special items. Adjusted EBITDA margin is calculated as Adjusted EBITDA divided by Reported Net Sales. See the reconciliation under “Non-U.S. GAAP Measures.”
Net sales for the Aptar Pharma segment increased 8% in the third quarter of 2024 to $420.6 million compared to $389.2 million in the third quarter of 2023. Changes in currencies positively affected net sales by 1%. Therefore, core sales increased by 7% in the third quarter of 2024 compared to the third quarter of 2023. The majority of the sales growth is due to higher volumes in our prescription drug and active material science solutions divisions. Core sales of our products to the prescription drug market increased 20% on strong demand for our products used on emergency medicines, central nervous system and allergic rhinitis applications along with higher customer royalties. The 6% core sales decline in the consumer health care market was driven by a non-product service payment in 2023 that didn't repeat. Sales of our products and services to the injectables market decreased 12%. While product sales were off slightly, the injectables division faced a difficult comparison over the prior year period due to service revenue for a customer's product launch that did not repeat. Active material science solutions increased 10% mainly on strong growth in our probiotic applications. Digital Health currently does not represent a significant percentage of the total Pharma sales.
34
Table of Contents
Third Quarter 2024
Net Sales Change over Prior Year		Prescription
Drug		Consumer
Health Care		InjectablesActive Material Science SolutionsDigital HealthTotal
Reported Net Sales Growth21 %(4)%(11)%11 %212 %8 %
Currency Effects (1)(1)%(2)%(1)%(1)%(3)%(1)%
Core Sales Growth20 %(6)%(12)%10 %209 %7 %
Net sales for the first nine months of 2024 increased by 9% to $1.24 billion compared to $1.14 billion in the first nine months of 2023. Changes in currency rates did not impact net sales during the first nine months of 2024. Therefore, core sales also increased by 9% in the first nine months of 2024 compared to the same period in the prior year. Core sales of products included in our prescription drug division increased 16% on continued strong demand for our allergic rhinitis, central nervous system and emergency medicine systems and higher customer royalties. Core sales in the consumer health care market were flat as higher demand for our nasal decongestant and eye care solutions was offset by lower sales of dermal and cough and cold products. Core sales of our products to the injectables market improved by 5% due primarily to the prior year shutdown of operations for the implementation of our new ERP system, which more than compensated for service revenue that did not repeat. Core sales of our active material science solutions increased 6% mainly on growth in our probiotics, diabetes and oral solid dose applications after a period of destocking.
Nine Months Ended September 30, 2024
Net Sales Change over Prior Year		Prescription
Drug		Consumer
Health Care		InjectablesActive Material Science SolutionsDigital HealthTotal
Reported Net Sales Growth16 %1 %5 %6 %72 %9 %
Currency Effects (1)— %(1)%— %— %— %— %
Core Sales Growth16 %— %5 %6 %72 %9 %
_______________________________________
(1)Currency effects are calculated by translating last year’s amounts at this year’s foreign exchange rates.
Adjusted EBITDA in the third quarter of 2024 increased 11% to $151.6 million compared to $136.3 million in the same period of the prior year. This increase was mainly due to the profitability on strong prescription drug division and active material science solutions sales growth along with higher customer royalties discussed above. Our Adjusted EBITDA margin improved to 36.0% in the third quarter of 2024 from 35.0% in the third quarter of 2023 mainly on the strength of our higher value proprietary dispensing device sales and higher customer royalties.
Adjusted EBITDA in the first nine months of 2024 increased 14% to $425.3 million compared to $371.5 million in the same period of the prior year. This positive impact was mainly due to the profitability on strong core sales growth in prescription, injectables and active material solutions. During the prior year, we also incurred additional expenses related to our injectables ERP system implementation which did not repeat. Overall, our Adjusted EBITDA margin improved to 34.2% in the first nine months of 2024 compared to 32.7% in the first nine months of 2023.
APTAR BEAUTY SEGMENT
Operations that sell dispensing systems and sealing solutions to the beauty, personal care and home care markets form our Aptar Beauty segment.
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Net Sales$302,859 $323,980 $951,666 $979,956 
Adjusted EBITDA (1)40,221 41,070 125,993 121,375 
Adjusted EBITDA margin (1)13.3 %12.7 %13.2 %12.4 %
________________________________________________
(1)Adjusted EBITDA is calculated as earnings before net interest, taxes, depreciation, amortization, restructuring initiatives, acquisition-related costs, net unrealized investment gains and losses related to observable market price changes on equity securities and other special items. Adjusted EBITDA margin is calculated as Adjusted EBITDA divided by Reported Net Sales. See the reconciliation under “Non-U.S. GAAP Measures.”
35
Table of Contents
Reported net sales for the quarter ended September 30, 2024 decreased 7% to $302.9 million compared to $324.0 million in the third quarter of the prior year. Changes in currency rates negatively impacted net sales by 1% in the third quarter of 2024. Therefore, core sales decreased 6% in the third quarter of 2024 compared to the same quarter of the prior year. Lower tooling sales negatively impacted overall third quarter 2024 Beauty net sales by 4%, while product sales decreased by the remaining 2%. Regionally, improving results in North America were offset in Europe by difficult comparisons to the prior year period. Core sales of our products to the beauty market decreased 14% due to lower sales in prestige fragrance after a high demand of new product launches during the same period in 2023. Personal care improved by 5% on strong sales of our hair care and body and skin care applications, while home care core sales increased 18% on higher demand for our air care and automotive, industrial and paint products, mainly in North America.
Third Quarter 2024
Net Sales Change over Prior Year		Personal
Care		BeautyHome
Care		Total
Reported Net Sales Growth4 %(14)%17 %(7)%
Currency Effects (1)1 %— %1 %1 %
Core Sales Growth5 %(14)%18 %(6)%
For the first nine months of 2024, reported net sales of $951.7 million decreased 3% compared to $980.0 million reported in the first nine months of the prior year. Changes in currency rates and our acquisition of iD SCENT did not have an impact on segment sales. Therefore, core sales also decreased 3% in the first nine months of 2024 compared to the same period in the prior year. Core sales of our products to the beauty market during the first nine months of 2024 decreased 7% due to the lower tooling sales and difficult European comparisons to prior year mentioned above. Personal care core sales improved 1% over the prior year as higher sales of our body and skin care products more than compensated for lower sales of our sun care and personal cleansing applications. Core sales of our home care market products improved 10% on higher demand from our customers selling air care and automotive products.
Nine Months Ended September 30, 2024
Net Sales Change over Prior Year		Personal
Care		BeautyHome
Care		Total
Reported Net Sales Growth1 %(7)%10 %(3)%
Currency Effects (1)— %— %— %— %
Acquisitions— %— %— %— %
Core Sales Growth1 %(7)%10 %(3)%
________________________________________________
(1)Currency effects are calculated by translating last year’s amounts at this year’s foreign exchange rates.
Adjusted EBITDA in the third quarter of 2024 decreased 2% to $40.2 million compared to $41.1 million in the same period in the prior year. This is primarily attributable to the lower tooling sales and difficult comparisons to prior year prestige fragrance sales discussed above along with rising input costs, which more than offset our improved operational performance and benefits realized from our cost management initiatives during the third quarter of 2024. However, these operational improvements lead to our Adjusted EBITDA margin increasing from 12.7% in the third quarter of 2023 to 13.3% during the third quarter of 2024.
Adjusted EBITDA in the first nine months of 2024 increased 4% to $126.0 million compared to $121.4 million reported in the same period in the prior year. This increase was mainly due to improved operational performance along with benefits realized from our cost management initiatives, which more than compensated for rising input costs. Therefore, our Adjusted EBITDA margin improved from 12.4% in the first nine months of 2023 to 13.2% during the first nine months of 2024.
36
Table of Contents
APTAR CLOSURES SEGMENT
Operations that sell dispensing closures, sealing solutions and food service trays to the food, beverage, personal care, home care, beauty and healthcare markets form our Aptar Closures segment. Aptar's food protection business and elastomeric flow-control technology business continue to report through the Aptar Closures segment.
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Net Sales$185,838 $179,829 $540,716 $533,080 
Adjusted EBITDA (1)31,980 27,607 86,259 81,387 
Adjusted EBITDA margin (1)17.2 %15.4 %16.0 %15.3 %
________________________________________________
(1)Adjusted EBITDA is calculated as earnings before net interest, taxes, depreciation, amortization, restructuring initiatives, acquisition-related costs, net unrealized investment gains and losses related to observable market price changes on equity securities and other special items. Adjusted EBITDA margin is calculated as Adjusted EBITDA divided by Reported Net Sales. See the reconciliation under “Non-U.S. GAAP Measures.”
Reported sales for the quarter ended September 30, 2024 increased approximately 3% to $185.8 million compared to $179.8 million in the third quarter of the prior year. Changes in currency rates negatively impacted net sales by 1%. Therefore, core sales for the third quarter of 2024 increased approximately 4% from the same quarter of the prior year. The majority of the increase during the current quarter is due to higher product sales. Sales to the food market increased 10% on higher sales of our dispensing closures used on sauces and condiments, spreads, jellies and honey and dairy products. The 1% increase in beverage market sales was mainly due to higher sales of our closures on functional drink products. Personal care sales declined 3% mainly due to lower demand for our skin care and hair care closures. Other sales decreased 3% on lower sales of our dish care products as we realized strong demand from a new product launch during the third quarter of 2023.
Third Quarter 2024
Net Sales Change over Prior Year		FoodBeveragePersonal CareOther (2)Total
Reported Net Sales Growth9 %— %(5)%(3)%3 %
Currency Effects (1)1 %1 %2 %— %1 %
Core Sales Growth10 %1 %(3)%(3)%4 %
Net sales for the first nine months of 2024 increased approximately 1% to $540.7 million compared to $533.1 million in the first nine months of 2023. Changes in currency rates negatively impacted net sales by 1% while our acquisition of Gulf Closures had no significant impact on net sales. Therefore, core sales increased approximately 2% in the first nine months of 2024 compared to the same period in the prior year. Core sales to the food market improved 3% compared to prior year on strong sales of our closures on sauces and condiments, dry spices and seasonings products. Core sales to our beverage customers increased 1% in the first nine months of 2024 compared to the same period of the prior year on improving bottled water and functional drink sales. Personal care declined slightly on lower sales of our hair care solutions, while other sales were consistent with prior year as strong sales of our laundry care products offset slightly lower sales of our dish care applications after the 2023 product launch mentioned above.
Nine Months Ended September 30, 2024
Net Sales Change over Prior Year		FoodBeveragePersonal CareOther (2)Total
Reported Net Sales Growth3 %2 %(2)%(1)%1 %
Currency Effects (1)— %— %1 %1 %1 %
Acquisitions— %(1)%— %— %— %
Core Sales Growth3 %1 %(1)%— %2 %
______________________________________________________________
(1)Currency effects are calculated by translating last year’s amounts at this year’s foreign exchange rates.
(2)Other includes beauty, home care and healthcare markets.
Adjusted EBITDA in the third quarter of 2024 increased 16% to $32.0 million compared to $27.6 million reported in the same period of the prior year. Sales growth, operational improvements and cost containment initiatives more than compensated for a $0.6 million negative resin impact due to timing of cost pass-throughs to our customers. Therefore, our Adjusted EBITDA margin improved from 15.4% in the third quarter of 2023 to 17.2% during the third quarter of 2024.
37
Table of Contents
Adjusted EBITDA in the first nine months of 2024 increased 6% to $86.3 million compared to $81.4 million reported in the same period of the prior year. Our profitability was positively impacted by the higher sales along with operational improvements and containing costs discussed above. These improvements more than compensate for a negative resin pass-through impact of $2.5 million. This led to our Adjusted EBITDA margin improving from 15.3% in the first nine months of 2023 to 16.0% during the first nine months of 2024.
CORPORATE & OTHER
In addition to our three reporting segments, we assign certain costs to “Corporate & Other,” which is presented separately in Note 16 – Segment Information of the Notes to the Condensed Consolidated Financial Statements. For Corporate & Other, Adjusted EBITDA (which excludes net interest, taxes, depreciation, amortization, restructuring initiatives, acquisition-related costs, net unrealized investment gains and losses related to observable market price changes on equity securities and other special items) primarily includes certain professional fees, compensation and information system costs which are not allocated directly to our reporting segments.
For the quarter ended September 30, 2024, Corporate & Other Adjusted EBITDA increased to $15.4 million of expense from $11.7 million of expense in the third quarter of 2023. During the prior year period, we recognized approximately $4.2 million of realized gains on the sale of shares related to our investment in PureCycle which drove the majority of the year over year change.
Corporate & Other Adjusted EBITDA in the first nine months of 2024 increased to $57.5 million of expense compared to $46.0 million of expense reported in the same period of the prior year. As mentioned above, we realized a $4.2 million gain on sales of PureCycle shares last year. During 2024, we recognized approximately $3.4 million of costs to evaluate potential acquisition targets. We also incurred higher incentive compensation costs, including accruals related to our current short-term and equity compensation programs during the current year period.
NON-U.S. GAAP MEASURES
In addition to the information presented herein that conforms to U.S. GAAP, we also present financial information that does not conform to U.S. GAAP, which are referred to as non-U.S. GAAP financial measures. Management may assess our financial results both on a U.S. GAAP basis and on a non-U.S. GAAP basis. We believe it is useful to present these non-U.S. GAAP financial measures because they allow for a better period over period comparison of operating results by removing the impact of items that, in management’s view, do not reflect our core operating performance. These non-U.S. GAAP financial measures should not be considered in isolation or as a substitute for U.S. GAAP financial results, but should be read in conjunction with the unaudited Condensed Consolidated Statements of Income and other information presented herein. Investors are cautioned against placing undue reliance on these non-U.S. GAAP measures. Further, investors are urged to review and consider carefully the adjustments made by management to the most directly comparable U.S. GAAP financial measures to arrive at these non-U.S. GAAP financial measures.
In our Management’s Discussion and Analysis, we exclude the impact of foreign currency translation when presenting net sales and other information, which we define as “constant currency.” Core sales, which excludes the impact of foreign currency translation is a non-U.S. GAAP financial measure. Core sales growth is calculated as current period core sales less prior period core sales divided by prior period core sales multiplied by a hundred. As a worldwide business, it is important that we take into account the effects of foreign currency translation when we view our results and plan our strategies. Consequently, when our management looks at our financial results to measure the core performance of our business, we may exclude the impact of foreign currency translation by translating our prior period results at current period foreign currency exchange rates. As a result, our management believes that these presentations are useful internally and may be useful to investors. We also exclude the impact of material acquisitions when comparing results to prior periods. Changes in operating results excluding the impact of acquisitions are non-U.S. GAAP financial measures. We believe it is important to exclude the impact of acquisitions on period over period results in order to evaluate performance on a more comparable basis.
We present earnings before net interest and taxes (“EBIT”) and earnings before net interest, taxes, depreciation and amortization (“EBITDA”). We also present our adjusted earnings before net interest and taxes (“Adjusted EBIT”) and adjusted earnings before net interest, taxes, depreciation and amortization (“Adjusted EBITDA”), both of which exclude restructuring initiatives, acquisition-related costs, purchase accounting adjustments related to acquisitions and investments and net unrealized investment gains and losses related to observable market price changes on equity securities. Our Outlook is also provided on a non-U.S. GAAP basis because certain reconciling items are dependent on future events that either cannot be controlled, such as exchange rates and changes in the fair value of equity investments, or reliably predicted because they are not part of our routine activities, such as restructuring initiatives and acquisition-related costs.
We provide a reconciliation of Net Debt to Net Capital as a non-U.S. GAAP measure. “Net Debt” is calculated as interest-bearing debt less cash and equivalents and short-term investments while “Net Capital” is calculated as stockholders’ equity plus Net Debt. Net Debt to Net Capital measures a company’s financial leverage, which gives users an idea of a company's financial structure, or how it is financing its operations, along with insight into its financial strength. We believe that it is meaningful to take into consideration the balance of our cash, cash equivalents and short-term investments when evaluating our leverage. If needed, such assets could be used to reduce our gross debt position.
38
Table of Contents
Finally, we provide a reconciliation of free cash flow as a non-U.S. GAAP measure. Free cash flow is calculated as cash provided by operating activities less capital expenditures plus proceeds from government grants related to capital expenditures. We use free cash flow to measure cash flow generated by operations that is available for dividends, share repurchases, acquisitions and debt repayment. We believe that it is meaningful to investors in evaluating our financial performance and measuring our ability to generate cash internally to fund our initiatives.
Three Months Ended
September 30, 2024
ConsolidatedAptar PharmaAptar BeautyAptar ClosuresCorporate & OtherNet Interest
Net Sales$909,291 $420,594 $302,859 $185,838 $— $— 
Reported net income$99,922 
Reported income taxes31,209 
Reported income before income taxes131,131 120,243 17,839 18,042 (15,725)(9,268)
Adjustments:
Restructuring initiatives3,864 564 1,962 877 461 
Curtailment gain related to restructuring initiatives(1,851)— — (1,851)— 
Net investment gain(1,043)(1,043)
Adjusted earnings before income taxes132,101 120,807 19,801 17,068 (16,307)(9,268)
Interest expense12,290 12,290 
Interest income(3,022)(3,022)
Adjusted earnings before net interest and taxes (Adjusted EBIT)141,369 120,807 19,801 17,068 (16,307)— 
Depreciation and amortization67,015 30,787 20,420 14,912 896 
Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA)$208,384 $151,594 $40,221 $31,980 $(15,411)$— 
Reported net income margin (Reported net income / Reported Net Sales)11.0 %
Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales)22.9 %36.0 %13.3 %17.2 %
39
Table of Contents
Three Months Ended
September 30, 2023
ConsolidatedAptar PharmaAptar BeautyAptar ClosuresCorporate & OtherNet Interest
Net Sales$892,997 $389,188 $323,980 $179,829 $— $— 
Reported net income$84,298 
Reported income taxes25,751 
Reported income before income taxes110,049 108,113 17,415 11,647 (18,088)(9,038)
Adjustments:
Restructuring initiatives6,161 92 2,880 3,098 91 
Net investment loss1,240 1,240 
Realized gain on investments included in net investment loss above4,188 4,188 
Adjusted earnings before income taxes121,638 108,205 20,295 14,745 (12,569)(9,038)
Interest expense9,984 9,984 
Interest income(946)(946)
Adjusted earnings before net interest and taxes (Adjusted EBIT)130,676 108,205 20,295 14,745 (12,569)— 
Depreciation and amortization62,686 28,139 20,775 12,862 910 
Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA)$193,362 $136,344 $41,070 $27,607 $(11,659)$— 
Reported net income margin (Reported net income / Reported Net Sales)9.4 %
Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales)21.7 %35.0 %12.7 %15.4 %
40
Table of Contents
Nine Months Ended
September 30, 2024
ConsolidatedAptar PharmaAptar BeautyAptar ClosuresCorporate & OtherNet Interest
Net Sales$2,734,802 $1,242,420 $951,666 $540,716 $— $— 
Reported net income$273,313 
Reported income taxes80,382 
Reported income before income taxes353,695 335,409 57,808 42,883 (58,901)(23,504)
Adjustments:
Restructuring initiatives9,659 653 5,871 2,530 605 
Curtailment gain related to restructuring initiatives(1,851)— — (1,851)— 
Net investment gain
(1,495)(1,495)
Transaction costs related to acquisitions140 — 140 — — 
Adjusted earnings before income taxes360,148 336,062 63,819 43,562 (59,791)(23,504)
Interest expense32,526 32,526 
Interest income(9,022)(9,022)
Adjusted earnings before net interest and taxes (Adjusted EBIT)383,652 336,062 63,819 43,562 (59,791)— 
Depreciation and amortization196,332 89,198 62,174 42,697 2,263 
Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA)$579,984 $425,260 $125,993 $86,259 $(57,528)$— 
Reported net income margin (Reported net income / Reported Net Sales)10.0 %
Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales)21.2 %34.2 %13.2 %16.0 %
41
Table of Contents
Nine Months Ended
September 30, 2023
ConsolidatedAptar PharmaAptar BeautyAptar ClosuresCorporate & OtherNet Interest
Net Sales$2,648,970 $1,135,934 $979,956 $533,080 $— $— 
Reported net income$221,931 
Reported income taxes72,265 
Reported income before income taxes294,196 288,603 46,643 39,174 (52,590)(27,634)
Adjustments:
Restructuring initiatives19,628 1,657 12,650 4,060 1,261 
Net investment gain(1,839)(1,839)
Realized gain on investments included in net investment gain above4,188 4,188 
Transaction costs related to acquisitions255 — 199 56 — 
Adjusted earnings before income taxes316,428 290,260 59,492 43,290 (48,980)(27,634)
Interest expense29,900 29,900 
Interest income(2,266)(2,266)
Adjusted earnings before net interest and taxes (Adjusted EBIT)344,062 290,260 59,492 43,290 (48,980)— 
Depreciation and amortization184,212 81,248 61,883 38,097 2,984 
Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA)$528,274 $371,508 $121,375 $81,387 $(45,996)$— 
Reported net income margin (Reported net income / Reported Net Sales)8.4 %
Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales)19.9 %32.7 %12.4 %15.3 %
Net Debt to Net Capital ReconciliationSeptember 30,December 31,
20242023
Revolving credit facility and overdrafts
$222,817 $81,794 
Current maturities of long-term obligations, net of unamortized debt issuance costs30,295 376,426 
Long-Term Obligations, net of unamortized debt issuance costs822,731 681,188 
Total Debt1,075,843 1,139,408 
Less:
Cash and equivalents325,524 223,643 
Net Debt$747,932 $915,765 
Total Stockholders' Equity$2,553,641 $2,321,298 
Net Debt747,932 915,765 
Net Capital$3,301,573 $3,237,063 
Net Debt to Net Capital22.7 %28.3 %
42
Table of Contents
Free Cash Flow ReconciliationSeptember 30,September 30,
20242023
Net Cash Provided by Operations$465,174 $355,602 
Capital Expenditures(210,416)(231,199)
Free Cash Flow$254,758 $124,403 
FOREIGN CURRENCY
Because of our international presence, movements in exchange rates may have a significant impact on the translation of the financial statements of our foreign subsidiaries. Our primary foreign exchange exposure is to the euro, but we also have foreign exchange exposure to the Chinese yuan, Brazilian real, Mexican peso, Swiss franc and other Asian, European and South American currencies. A weakening U.S. dollar has an additive effect. Conversely, a strengthening U.S. dollar relative to foreign currencies has a dilutive translation effect on our financial statements. In some cases, we sell products denominated in a currency different from the currency in which the related costs are incurred. Any changes in exchange rates on such inter-country sales could materially impact our results of operations. During the third quarter ended September 30, 2024, the U.S. dollar was weaker compared to most European currencies and the Chinese yuan while strengthening against most Latin American currencies, except for the Brazilian real. During the nine months ended September 30, 2024, the U.S. dollar was stronger compared to all currencies except the Colombian and Mexican pesos, Swiss franc and the British pound. This resulted in a neutral impact on our translated results during the third quarter and year-to-date period of 2024 when compared to the third quarter and year-to-date period of 2023.
QUARTERLY TRENDS
Our results of operations in the fourth quarter of the year are typically negatively impacted by customer plant shutdowns in December. Several of the markets we serve are impacted by the seasonality of underlying consumer products. This, in turn, may have an impact on our net sales and results of operations for those markets. The diversification of our product portfolio minimizes fluctuations in our overall quarterly financial statements and results in an immaterial seasonality impact on our Condensed Consolidated Financial Statements when viewed quarter over quarter.
Generally, we have incurred higher stock-based compensation expense in the first quarter compared with the rest of the fiscal year due to the timing and recognition of stock-based expense from substantive vesting for retirement eligible employees. As of September 30, 2024, our estimated stock-based compensation expense on a pre-tax basis for the year 2024 compared to 2023 is as follows:
20242023
First Quarter$18,276 $15,042 
Second Quarter9,277 10,391 
Third Quarter10,409 10,051 
Fourth Quarter (estimated for 2024)9,506 5,809 
$47,468 $41,293 
LIQUIDITY AND CAPITAL RESOURCES
Given our current level of leverage and our ability to generate cash flow from operations, we believe we are in a strong financial position to meet our business requirements in the foreseeable future. We have historically used cash flow from operations, our revolving and other credit facilities, proceeds from stock options and debt, as needed, as our primary sources of liquidity. Our primary uses of cash are to invest in equipment and working capital for the continued growth of our business, including facilities that are necessary to support our growth, pay quarterly dividends to stockholders, to make acquisitions and repurchase shares of our common stock that will contribute to the achievement of our strategic objectives. Due to uncertain macroeconomic conditions, including rising interest rates and the inflationary environment, in the event that customer demand decreases significantly for a prolonged period of time and adversely impacts our cash flows from operations, we would have the ability to restrict and significantly reduce capital expenditure levels and share repurchases, as well as reevaluate our acquisition strategy. A prolonged and significant reduction in capital expenditure levels could increase future repairs and maintenance costs as well as have a negative impact on operating margins if we were unable to invest in new innovative products.
Cash and equivalents and restricted cash increased to $325.5 million at September 30, 2024 from $223.6 million at December 31, 2023. Total short and long-term interest-bearing debt decreased from $1.14 billion at December 31, 2023 to $1.08 billion at September 30, 2024. The ratio of our Net Debt (interest-bearing debt less cash and cash equivalents) to Net Capital (stockholders’ equity plus Net Debt) decreased to 22.7% at September 30, 2024 from 28.3% at December 31, 2023. See the reconciliation under “Non-U.S. GAAP Measures.”
43
Table of Contents
In the first nine months of 2024, our operations provided approximately $465.2 million in net cash flow compared to $355.6 million for the same period a year ago. In both periods, cash flow from operations was primarily derived from earnings before depreciation and amortization and better working capital management.
We used $225.7 million in cash for investing activities during the first nine months of 2024 compared to $239.3 million during the same period a year ago. Our investment in capital projects decreased $20.8 million during the first nine months of 2024 compared to the first nine months of 2023 as we completed larger projects that had significant spend in the prior year. The capital expenditures accrued within accounts payable, accrued and other liabilities was $21.3 million as of September 30, 2024 compared to $20.1 million as of September 30, 2023.
Financing activities used $137.7 million in cash during the first nine months of 2024 compared to $94.0 million in cash used by financing activities during the same period a year ago. The increased use of cash in the first nine months of 2024 is primarily related to the debt refinancing of $100.0 million of Senior Unsecured Notes in the first quarter of 2024, €200 million of Senior Unsecured Notes in the second quarter of 2024 and $50.0 million of Senior Unsecured Notes in the third quarter of 2024. This was partially offset by the new term loan of $166.0 million and increased borrowings on our amended revolving credit facility of $14.5 million.
In October 2020, we entered into an unsecured money market borrowing arrangement to provide short-term financing of up to $30 million that is available in the U.S. No borrowing on this facility is permitted over a quarter end date. As such, no balance was utilized under this arrangement as of September 30, 2024.
Aptar has a revolving credit facility (the “revolving credit facility”) with a syndicate of banks which provides us with unsecured financing of up to $600 million, which may be increased by up to $300 million subject to certain conditions. The revolving credit facility is available in the U.S. and to our wholly-owned UK subsidiary and can be drawn in various currencies including USD, EUR, GBP, and CHF. The revolving credit facility was set to mature in June 2026, but on July 2, 2024, we entered into a new amended and restated agreement (the “amended revolving credit facility”) that extended the maturity date to July 2029, subject to a maximum of two one-year extensions in certain circumstances, As of December 31, 2023, Aptar had utilized $36.5 million and €40.0 million ($44.2 million) under the revolving credit facility in the U.S. and no balance was utilized by our wholly-owned UK subsidiary. As of September 30, 2024, Aptar had utilized €200 million ($222.7 million) under the revolving credit facility in the U.S. and no balance was utilized by our wholly-owned UK subsidiary.
On July 2, 2024, we entered into a term loan with a syndicate of banks (the “Term Loan”). The Term Loan matures in July 2027 and enabled drawings on the loan until September 30, 2024 and provided for unsecured financing of up to $330 million available in the U.S. Funds are to be used to refinance near-term maturities and for general corporate purposes. As of September 30, 2024, $166 million was utilized under the Term Loan facility and the unused portion expired.
There are no compensating balance requirements associated with our amended revolving credit facility. Each borrowing under the revolving credit facility will bear interest at rates based on SOFR (in the case of USD), EURIBOR (in the case of EUR), SONIA (in the case of GBP), SARON (in the case of CHF), prime rates or other similar rates, in each case plus an applicable margin. The amended revolving credit facility also provides mechanics relating to a transition away from designated benchmark rates for other available currencies and the replacement of any such applicable benchmark by a replacement alternative benchmark rate or mechanism for loans made in the applicable currency. A facility fee on the total amount of the amended revolving credit facility is also payable quarterly, regardless of usage. The applicable margins for borrowings under the amended revolving credit facility and the facility fee percentage may change from time to time depending on changes in our consolidated leverage ratio. Credit facility balances are included in revolving credit facility and overdrafts on the Condensed Consolidated Balance Sheets.
Our revolving credit facility and corporate long-term obligations require us to satisfy certain financial and other covenants including:
RequirementLevel at September 30, 2024
Consolidated Leverage Ratio (1)Maximum of 3.50 to 1.001.10 to 1.00
Consolidated Interest Coverage Ratio (1)Minimum of 3.00 to 1.0016.81 to 1.00
__________________________________________________________
(1)Definitions of ratios are included as part of the amended revolving credit facility agreement and private placement agreements.
Based upon the above consolidated leverage ratio covenant, we would have the ability to borrow approximately an additional $1.7 billion before the 3.50 to 1.00 maximum ratio requirement would be exceeded.
On July 6, 2022, we entered into an agreement to swap approximately $200 million of our fixed USD debt to fixed EUR debt which would generate interest savings of approximately $0.5 million per quarter based upon exchange rates as of the transaction date.
44
Table of Contents
On October 10, 2024, the Board of Directors declared a quarterly cash dividend of $0.45 per share payable on November 14, 2024 to stockholders of record as of October 24, 2024.
Our foreign operations have historically met cash requirements with the use of internally generated cash or uncommitted short-term borrowings. We also have committed financing arrangements in both the U.S. and the UK as detailed above. We manage our global cash requirements considering (i) available funds among the many subsidiaries through which we conduct business, (ii) the geographic location of our liquidity needs, and (iii) the cost to access international cash balances.
CONTINGENCIES
The Company, in the normal course of business, is subject to a number of lawsuits and claims both actual and potential in nature. Please refer to Note 12 - Commitments and Contingencies of the Notes to Condensed Consolidated Financial Statements for a discussion of contingencies affecting our business.
RECENTLY ISSUED ACCOUNTING STANDARDS
We have reviewed the recently issued ASUs to the FASB’s Accounting Standards Codification that have future effective dates. Standards that have been adopted during 2024 are discussed in Note 1 – Summary of Significant Accounting Policies of the Notes to Condensed Consolidated Financial Statements.
Other accounting standards that have been issued by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our Condensed Consolidated Financial Statements upon adoption.
OUTLOOK
We expect earnings per share for the fourth quarter of 2024, excluding any restructuring expenses, changes in the fair value of equity investments and acquisition costs, to be in the range of $1.22 to $1.30 and this guidance is based on an effective tax rate range of 20% to 22%. Our total 2024 estimated cash outlays for capital expenditures net of government grant proceeds are expected to be approximately $280 million to $300 million.
FORWARD-LOOKING STATEMENTS
Certain statements in Management’s Discussion and Analysis and other sections of this Form 10-Q are forward-looking and involve a number of risks and uncertainties, including certain statements set forth in the Significant Developments, Restructuring Initiatives, Quarterly Trends, Liquidity and Capital Resources, Contingencies and Outlook sections of this Form 10-Q. Words such as “expects,” “anticipates,” “believes,” “estimates,” “future,” “potential”, “are optimistic” and other similar expressions or future or conditional verbs such as “will,” “should,” “would” and “could” are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results or other events may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to:
•geopolitical conflicts worldwide including the invasion of Ukraine by the Russian military and the recent events in the Middle East and the resulting indirect impact on demand from our customers selling their products into these countries, as well as rising input costs and certain supply chain disruptions;
•the availability of raw materials and components (particularly from sole sourced suppliers for some of our Pharma solutions) as well as the financial viability of these suppliers;
•lower demand and asset utilization due to an economic recession either globally or in key markets we operate within;
•economic conditions worldwide, including inflationary conditions and potential deflationary conditions in other regions we rely on for growth;
•the execution of our fixed cost reduction initiatives, including our optimization initiative;
•cybersecurity threats against our systems and/or service providers that could impact our networks and reporting systems;
•our ability to successfully implement facility expansions and new facility projects;
•fluctuations in the cost of materials, components, transportation cost as a result of supply chain disruptions and labor shortages, and other input costs (particularly resin, metal, anodization costs and energy costs);
•significant fluctuations in foreign currency exchange rates or our effective tax rate;
•the impact of tax reform legislation, changes in tax rates and other tax-related events or transactions that could impact our effective tax rate and cash flow;
•financial conditions of customers and suppliers;
•consolidations within our customer or supplier bases;
•changes in customer and/or consumer spending levels;
•loss of one or more key accounts;
•our ability to offset inflationary impacts with cost containment, productivity initiatives and price increases;
•changes in capital availability or cost, including rising interest rates;
•volatility of global credit markets;
45
Table of Contents
•our ability to identify potential new acquisitions and to successfully acquire and integrate such operations, including the successful integration of the businesses we have acquired;
•our ability to build out acquired businesses and integrate the product/service offerings of the acquired entities into our existing product/service portfolio;
•direct or indirect consequences of acts of war, terrorism or social unrest;
•the impact of natural disasters and other weather-related occurrences;
•fiscal and monetary policies and other regulations;
•changes, difficulties or failures in complying with government regulation, including FDA or similar foreign governmental authorities;
•changing regulations or market conditions regarding environmental sustainability;
•work stoppages due to labor disputes;
•competition, including technological advances;
•our ability to protect and defend our intellectual property rights, as well as litigation involving intellectual property rights;
•the outcome of any legal proceeding that has been or may be instituted against us and others;
•our ability to meet future cash flow estimates to support our goodwill impairment testing;
•the demand for existing and new products;
•the success of our customers’ products, particularly in the pharmaceutical industry;
•our ability to manage worldwide customer launches of complex technical products, particularly in developing markets;
•difficulties in product development and uncertainties related to the timing or outcome of product development;
•significant product liability claims; and
•other risks associated with our operations.
Although we believe that our forward-looking statements are based on reasonable assumptions, there can be no assurance that actual results, performance or achievements will not differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements. We undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Please refer to Item 1A (Risk Factors) of Part I included in our Annual Report on Form 10-K for the year ended December 31, 2023 for additional risks and uncertainties that may cause our actual results or other events to differ materially from those expressed or implied in such forward-looking statements.
46
Table of Contents
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
A significant number of our operations are located outside of the United States. Because of this, movements in exchange rates may have a significant impact on the translation of the financial condition and results of operations of our subsidiaries. Our primary foreign exchange exposure is to the euro, but we also have foreign exchange exposure to the Chinese yuan, Brazilian real, Argentine peso, Mexican peso, Swiss franc and other Asian, European and Latin American currencies. A strengthening U.S. dollar relative to foreign currencies has a dilutive translation effect on our financial statements. Conversely, a weakening U.S. dollar has an additive effect. Additionally, in some cases, we sell products denominated in a currency different from the currency in which the related costs are incurred. Any changes in exchange rates on such inter-country sales may impact our results of operations.
The table below provides information as of September 30, 2024 about our forward currency exchange contracts. The majority of the contracts expire before the end of the fourth quarter of 2024.
Buy/SellContract Amount
(in thousands)		Average
Contractual
Exchange Rate		Min / Max
Notional
Volumes
EUR / USD$18,014 1.1003 
16,363 - 38,873
MXN / USD13,000 0.0539 13,000 - 13,000
CZK / EUR11,926 0.0395 9,808 - 12,138
EUR / BRL10,485 6.1288 10,030 - 10,485
USD / EUR4,918 0.9089 4,379 - 9,706
CHF / EUR4,655 1.0443 3,481 - 4,655
EUR / CNY4,298 7.8244 4,298 - 5,372
EUR / THB4,168 38.4985 3,762 - 4,168
USD / CNY2,000 7.1418 2,000 - 2,940
EUR / MXN1,340 21.0235 541 - 1,340
GBP / EUR1,315 1.1760 0 - 1,315
USD / GBP362 0.7627 41 - 362
EUR / GBP268 0.8429 268 - 3,885
CZK / USD213 0.0444 0 - 213
EUR / CHF204 0.9370 0 - 204
USD / CHF
2 0.8422 0 - 2
Total$77,168 
As of September 30, 2024, we have recorded the fair value of foreign currency forward exchange contracts of $0.1 million in prepaid and other and $1.1 million in accounts payable, accrued and other liabilities on the Condensed Consolidated Balance Sheets. On July 6, 2022, we entered into a seven year USD/EUR fixed-to-fixed cross currency interest rate swap to effectively hedge the interest rate exposure relating to $203 million of the $400 million 3.60% Senior Notes due March 2032 which were issued by AptarGroup, Inc. on March 7, 2022. This USD/EUR swap agreement exchanged $203 million of fixed-rate 3.60% USD debt to €200 million of fixed-rate 2.5224% EUR debt. The fair value of this net investment hedge is $22.5 million reported in accounts payable, accrued and other liabilities on the Condensed Consolidated Balance Sheets.
ITEM 4. CONTROLS AND PROCEDURES
DISCLOSURE CONTROLS AND PROCEDURES
Management has evaluated, with the participation of the chief executive officer and chief financial officer of the Company, the effectiveness of our disclosure controls and procedures (as that term is defined in Rule 13a-15(e) under the Securities Exchange Act of 1934) as of September 30, 2024. Based on that evaluation, the chief executive officer and chief financial officer have concluded that these controls and procedures were effective as of such date.
CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING
During the fiscal quarter ended September 30, 2024, we implemented ERP systems at two operating units. Consequently, the control environments have been modified at these locations to incorporate the controls contained within the new ERP systems. Except for the foregoing, no changes in our internal control over financial reporting (as such term is defined in Rule 13a-15(f) under the Securities Exchange Act of 1934) occurred during our fiscal quarter ended September 30, 2024 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
47
Table of Contents
PART II - OTHER INFORMATION

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
RECENT SALES OF UNREGISTERED SECURITIES
Certain French employees are eligible to participate in the FCP Aptar Savings Plan (the “Plan”). An independent agent purchases shares of common stock available under the Plan for cash on the open market and we do not issue shares. We do not receive any proceeds from the purchase of common stock under the Plan. The agent under the Plan is BNP Paribas Fund Services. No underwriters are used under the Plan. All shares are sold in reliance upon the exemption from registration under the Securities Act of 1933 provided by Regulation S promulgated under that Act. During the quarter ended September 30, 2024, the Plan purchased no shares of our common stock on behalf of the participants, and sold 4,617 shares of our common stock on behalf of the participants at an average price of $150.16, for an aggregate amount of $693 thousand. At September 30, 2024, the Plan owned 108,693 shares of our common stock.
ISSUER PURCHASES OF EQUITY SECURITIES
Our previous $350 million share repurchase authorization approved in 2019 was replaced on October 10, 2024 with a new share purchase authorization of up to $500 million of common stock. This authorization replaces previous authorizations and has no expiration date. We may repurchase shares through the open market, privately negotiated transactions or other programs, subject to market conditions.
During the three and nine months ended September 30, 2024, we repurchased approximately 95 thousand shares for $14.2 million and 215 thousand shares for $31.3 million, respectively. As of September 30, 2024, there was $29.4 million of authorized share repurchases remaining under the existing authorization.
The following table summarizes our purchases of our securities for the quarter ended September 30, 2024:
PeriodTotal Number Of Shares PurchasedAverage Price Paid Per ShareTotal Number Of Shares Purchased As Part Of Publicly Announced Plans Or ProgramsDollar Value Of Shares That May Yet Be Purchased Under The Plans Or Programs
(in millions)
7/1/24 - 7/31/24
—$— —$43.5 
8/1/24 - 8/31/24
48,700147.07 48,70036.4 
9/1/24 - 9/30/24
46,300151.35 46,30029.4 
Total95,000$149.15 95,000$29.4 

48
Table of Contents
ITEM 5. OTHER INFORMATION
Rule 10b5-1 Plan Elections
During the three months ended September 30, 2024, no director or officer of the Company adopted, modified or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408 of Regulation S-K.
Amendment and Restatement of By-Laws
On October 23, 2024, the Board of Directors adopted amendments to the Company’s Amended and Restated By-Laws (the “Amended and Restated By-Laws”), effective immediately. The amendments:
•Update the existing procedural mechanics and disclosure requirements for stockholder nominations of directors and submissions of stockholder proposals (other than proposals to be included in the Company's proxy statement pursuant to Rule 14a-8 under the Securities Exchange Act of 1934, as amended) to, among other things, align such provisions with recent developments in Delaware law;
•Provide that the interview requirement for election or appointment to the Board of Directors is applicable to all director nominees; and
•Make various other non-substantive updates, including ministerial and conforming changes.
The foregoing summary of the amendments does not purport to be complete and is qualified in its entirety by reference to the complete text of the Amended and Restated By-Laws, which are attached hereto as Exhibit 3.1 and are incorporated herein by reference.
49
Table of Contents
ITEM 6. EXHIBITS
Exhibit 3.1*
Exhibit 10.1
Exhibit 10.2
Exhibit 10.3*
Exhibit 31.1*
Exhibit 31.2*
Exhibit 32.1*
Exhibit 32.2*
Exhibit 101
The following information from our Quarterly Report on Form 10-Q for the third quarter of fiscal 2024, filed with the SEC on October 25, 2024, formatted in Inline Extensible Business Reporting Language (XBRL): (i) the Cover Page, (ii) the Condensed Consolidated Statements of Income – Three and Nine Months Ended September 30, 2024 and 2023, (iii) the Condensed Consolidated Statements of Comprehensive Income – Three and Nine Months Ended September 30, 2024 and 2023, (iv) the Condensed Consolidated Balance Sheets – September 30, 2024 and December 31, 2023, (v) the Condensed Consolidated Statements of Changes in Equity – Three and Nine Months Ended September 30, 2024 and 2023, (vi) the Condensed Consolidated Statements of Cash Flows - Nine Months Ended September 30, 2024 and 2023 and (vii) the Notes to Condensed Consolidated Financial Statements.
Exhibit 104Cover Page Interactive Data File (embedded within the Inline XBRL document).
*Filed or furnished herewith.
**Management contract or compensatory plan or arrangement.

50
Table of Contents
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
AptarGroup, Inc.
(Registrant)
By/s/ ROBERT W. KUHN
Robert W. Kuhn
Executive Vice President and Chief Financial Officer
(Duly Authorized Officer and Principal Financial Officer)

Date: October 25, 2024

51